

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 30, 2004, 11:12:16 ; Search time 1701.11 Seconds
(without alignments)
2142.114 Million cell updates/sec

Title: US-09-529-397C-25

Perfect score: 100

Sequence: 1 gggaguggaggaaucaucg.....uagacagcaagcuucg 100

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 32822875 seqs, 1821965908 residues

Total number of hits satisfying chosen parameters: 65645750

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:*

1: gb_est1: *
2: gb_est2: *
3: gb_hic: *
4: gb_est3: *
5: gb_est4: *
6: gb_est5: *
7: gb_est6: *
8: gb_gss1: *
9: gb_gss2: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	34.6	34.6	642	BE147147	PM2-HT022
2	31.4	31.4	749	AG557770	Mus muscu
3	31.2	31.2	442	AZ955882	2M022110
4	30.8	30.8	696	B21536	F21F23-T7 I
5	30.6	30.6	461	CB736914	AMGRNUC:M
6	30.6	30.6	1074	BE371824	601217621
7	30.4	30.4	917	AG069018	Pan trogl
8	30.0	30.0	725	CK016754	AGENCOURT
9	29.8	29.8	528	AQ108017	CIT-HSP-2
10	29.6	29.6	578	CN553623	tae26908
11	29.6	29.6	617	BG38990	Gm01_Ole0
12	29.6	29.6	626	CN623811	tae59d12
13	29.6	29.6	717	CN553289	tae26908
14	29.6	29.6	744	CN226782	RJB004H01
15	29.6	29.6	745	CO421969	GGE2HT100
16	29.6	29.6	852	BU209960	603949556
17	29.6	29.6	877	BU399017	603534483
18	29.2	29.2	254	BM401540	JH3C07R S
19	29.2	29.2	343	BG630802	cC-esf1cL
20	29.2	29.2	762	CF446768	EST683113
21	29.0	29.0	715	BZ944697	CH240_121
22	28.8	28.8	339	CN464219	7866_1 Af
23	28.8	28.8	532	CA249234	SCSFL110
24	28.8	28.8	605	CE114143	tigr-gss-

25	28.8	28.8	739	8	CC115139	NDL.81L16
26	28.6	28.6	472	8	AQ955733	LEPAF67TR
27	28.6	28.6	513	5	BP051024	BP051024
c 28	28.6	28.6	559	6	CB094897	h276e08.b
c 29	28.6	28.6	561	8	BZ891642	CH240_287
c 30	28.4	28.4	580	8	EZ201271	CH230-351
31	28.4	28.4	607	6	CA892404	B0172B04-
32	28.4	28.4	629	6	CA890800	B0161F04-
33	28.4	28.4	629	6	CA892977	B0175H04-
c 34	28.4	28.4	748	9	AG525698	Mus muscu
35	28.4	28.4	756	4	BG393101	602411369
36	28.4	28.4	818	5	BU708057	UI-M-PR0-
c 37	28.4	28.4	832	9	CC491386	CH240_325
c 38	28.4	28.4	835	6	CB686108	CB686108
c 39	28.2	28.2	496	5	BQ531573	APX2_5 F
40	28.2	28.2	521	5	BQ531501	APX3_35
41	28.2	28.2	521	7	CF791691	MA
c 42	28.2	28.2	559	4	BG649176	EMI_77_E0
c 43	28.2	28.2	598	2	BE363373	WS1_62_B0
c 44	28.2	28.2	609	2	BE596636	P11_58_G0
c 45	28.2	28.2	625	6	CA267762	SCJLR207

ALIGNMENTS

RESULT 1
BE147147
LOCUS PM2-HT0224-291099-002-c09 HT0224 Homo sapiens cdNA, mRNA linear EST 21-JUN-2000
DEFINITION BE147147
ACCESSION BE147147
VERSION BE147147.1 GI:8609871
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS 1 (bases 1 to 642)
Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R., Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F., Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H., Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and Simpson,A.J.
TITLE Shotgun sequencing of the human transcriptome with ORF expressed sequence tags
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE 20202663
PUBMED 10737800
COMMENT Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP, Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=st3=PM2-HT0224-291099-002-c09&tl3=1999-10-29&tl4=1)
Seq primer: puc 18 forward
High quality sequence start: 17
High quality sequence stop: 415.
Location/Qualifiers
1..642
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/dev stage="Adult"
/clone_lib="HT0224"
/note=Organ: head neck; Vector: puc18; Site_1: SmaI;
Site_2: SmaI; A mini-library was made by cloning products


```

QY 7 GGAGGAUUAUCGAGGCAUAUUGCAGCUCCUUCUCAAACCAACGUAUAAUUGU 66
Db |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
272 GCAGGCTTTCATCCCGAGCACTGATTCCTGAGTCTTCATGATAAAATCTAACAAATTGAG 331
QY 67 UUUAGCAUAGCUCUAGGACAGCAGCUUCU 98
Db :::::||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
332 TTTTGTGTTTGTGTTTTCGAGACCAAGTTTCT 363

RESULT 4
B21536
LOCUS
DEFINITION F21F23-T7 IGF Arabidopsis thaliana genomic clone F21F23, genomic
survey sequence.
ACCESSION B21536
VERSION B21536.1 GI:2396590
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsiis.
REFERENCE 1 (bases 1 to 696)
AUTHORS Feng,J., Dewar,K., Buehler,E., Kim,C., Li,Y., Shinn,P., Sun,H. and
Ecker,J.
TITLE BAC End Sequences at ATGC
JOURNAL Unpublished (1997)
COMMENT Other GSSs: F21F23-Sp6
Contact: Ecker J.
Arabidopsis Thaliana Genome Center
University of Pennsylvania
Dept. of Biology, University of Pennsylvania, Philadelphia, PA
19104
Tel: 215-898-9384
Fax: 215-898-8780
Email: jecker@atgenome.bio.upenn.edu
Seq primer: T7
Class: BAC ends
High quality sequence start: 129
High quality sequence stop: 143.

FEATURES
source
1..696
Location/Qualifiers
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/ecotype="Columbia"
/db_xref="taxon:3702"
/clone="F21F23"
/sex="hermaphrodite"
/clone_lib="IGP"
/notes="Vector: BelobACII; Site_1: EcoRI; Site_2: EcoRI;
Produced by Thomas Altmann"

ORIGIN
Query Match 30.8%; Score 30.8; DB 8; Length 696;
Best Local Similarity 43.9%; Pred. No. 14;
Matches 29; Conservative 15; Mismatches 22; Indels 0; Gaps 0;

QY 9 AGAAUUAUCGAGGCAUAUUGCAGCUCCUUCUCAAACCAACGUAUAAUUGUUU 68
Db |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
306 AGAAATATCATCGATCAAGTAGAAGGTGTTGCTTCACCAACCATAGATGTGTC 365
QY 69 UAGCAU 74
Db ::|||:|||| 371

RESULT 5
CB736914/c
LOCUS
DEFINITION AMGNNUC-MRBE4-00015-C9-A rat brain E15 (10375) Rattus norvegicus
cDNA clone mrbe4-00015-c9 5', mRNA sequence.
ACCESSION CB736914
VERSION CB736914.1 GI:29804127

QY 7 GGAGGAUUAUCGAGGCAUAUUGCAGCUCCUUCUCAAACCAACGUAUAAUUGU 66
Db |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
272 GCAGGCTTTCATCCCGAGCACTGATTCCTGAGTCTTCATGATAAAATCTAACAAATTGAG 331
QY 67 UUUAGCAUAGCUCUAGGACAGCAGCUUCU 98
Db :::::||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
332 TTTTGTGTTTGTGTTTTCGAGACCAAGTTTCT 363

RESULT 4
B21536
LOCUS
DEFINITION F21F23-T7 IGF Arabidopsis thaliana genomic clone F21F23, genomic
survey sequence.
ACCESSION B21536
VERSION B21536.1 GI:2396590
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsiis.
REFERENCE 1 (bases 1 to 696)
AUTHORS Feng,J., Dewar,K., Buehler,E., Kim,C., Li,Y., Shinn,P., Sun,H. and
Ecker,J.
TITLE BAC End Sequences at ATGC
JOURNAL Unpublished (1997)
COMMENT Other GSSs: F21F23-Sp6
Contact: Ecker J.
Arabidopsis Thaliana Genome Center
University of Pennsylvania
Dept. of Biology, University of Pennsylvania, Philadelphia, PA
19104
Tel: 215-898-9384
Fax: 215-898-8780
Email: jecker@atgenome.bio.upenn.edu
Seq primer: T7
Class: BAC ends
High quality sequence start: 129
High quality sequence stop: 143.

FEATURES
source
1..696
Location/Qualifiers
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/ecotype="Columbia"
/db_xref="taxon:3702"
/clone="F21F23"
/sex="hermaphrodite"
/clone_lib="IGP"
/notes="Vector: BelobACII; Site_1: EcoRI; Site_2: EcoRI;
Produced by Thomas Altmann"

ORIGIN
Query Match 30.8%; Score 30.8; DB 8; Length 696;
Best Local Similarity 43.9%; Pred. No. 14;
Matches 29; Conservative 15; Mismatches 22; Indels 0; Gaps 0;

QY 9 AGAAUUAUCGAGGCAUAUUGCAGCUCCUUCUCAAACCAACGUAUAAUUGUUU 68
Db |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
306 AGAAATATCATCGATCAAGTAGAAGGTGTTGCTTCACCAACCATAGATGTGTC 365
QY 69 UAGCAU 74
Db ::|||:|||| 371

RESULT 5
CB736914/c
LOCUS
DEFINITION AMGNNUC-MRBE4-00015-C9-A rat brain E15 (10375) Rattus norvegicus
cDNA clone mrbe4-00015-c9 5', mRNA sequence.
ACCESSION CB736914
VERSION CB736914.1 GI:29804127

```

```

KEYWORDS EST.
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE 1 (bases 1 to 461)
AUTHORS Angen EST Program.
TITLE Angen Rat EST Program
JOURNAL Unpublished (2003)
COMMENT Contact: Dan Fitzpatrick
Angen, Inc
One Angen Center Drive, Thousand Oaks, CA 91320-1799, USA
Tel: 805 447-4881
Plate: 00015 row: C column: 9.
FEATURES
source
1..461
Location/Qualifiers
/organism="Rattus norvegicus"
/mol_type="mRNA"
/db_xref="taxon:10116"
/clone="mrbe4-00015-c9"
/tissue_type="brain E15"
/clone_lib="rat brain E15 (10375)"
/notes="Vector: pBCB; Site_1: BstXI; Site_2: NotI; rat
brain E15"

ORIGIN
Query Match 30.6%; Score 30.6; DB 6; Length 461;
Best Local Similarity 36.7%; Pred. No. 15;
Matches 29; Conservative 19; Mismatches 31; Indels 0; Gaps 0;

QY 8 GAGGAUUAUCGAGGCAUAUUGCAGCUCCUUCUCAAACCAACGUAUAAUUGUU 67
Db |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
180 GAGGACTTCATCAGTAGTGTGCGATAAATTATAGTCTTGACAGATTATGGTGAGTT 121
QY 68 UUAGCAUAGCUCUAGCGCA 86
Db ::|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
120 TGAGCAGTTGCATTAGCAA 102

RESULT 6
BE371824
LOCUS
DEFINITION 6U1217621F1 NCI_CGAP_Lu29 Mus musculus cDNA clone IMAGE:3586661 5',
mRNA sequence.
ACCESSION BE371824
VERSION BE371824.1 GI:9317291
KEYWORDS EST.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 1074)
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgaps-remail.nih.gov
Tissue Procurement: Gilbert Smith, Ph.D.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLAM8748 row: j column: 06
High quality sequence stop: 380.
FEATURES
source
1..1074
Location/Qualifiers
/organism="Mus musculus"
/mol_type="mRNA"
/strain="CZECH II"
/db_xref="taxon:10090"

```



```

RESULT 9
AQ108017/c
LOCUS
DEFINITION
  CIT-HSP-2374K6.TF CIT-HSP Homo sapiens genomic clone 2374K6,
  genomic survey sequence.
ACCESSION
  AQ108017
VERSION
  AQ108017.1 GI:3484196
KEYWORDS
  GSS.
SOURCE
  Homo sapiens (human)
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 (bases 1 to 528)
AUTHORS
  Adams,M.D., Rounsley,S.D., Zhao,S., Bass,S., Linher,K., Golden,K.,
  Berry,K., Granger,D., Suh,E., Wible,C., Shizuwa,H., Simon,M. and
  Venter,J.C.
TITLE
  Use of a random human BAC End Sequence Database for Sequence-Ready
  Map Building
JOURNAL
  Unpublished (1998)
COMMENT
  Other GSSs: CIT-HSP-2374K6.TR
  Contact: Mark Adams
  Department of Eukaryotic Genomics
  The Institute for Genomic Research
  9712 Medical Center Dr., Rockville, MD 20850, USA
  Tel: 301 838 0200
  Fax: 301 838 0208
  Email: mdadams@tigr.org
  Clones are available from Research Genetics (info@resgen.com). BAC
  end search page:
  http://www.tigr.org/tdb/hungen/bac_end_search/bac_end_search.html.
  Seq primer: MJ3-21
  Class: BAC ends.
FEATURES
      source
      Location/Qualifiers
          1..528
             /organism="Homo sapiens"
             /mol_type="genomic DNA"
             /db_xref="taxon:9606"
             /clone="2374K6"
             /sex="Male"
             /cell_type="Sperm"
             /clone_lib="CIT-HSP"
             /note="Vector: pBelobAC11; Site_1: HindIII; Site_2:
             HindIII"
ORIGIN
      Query Match      29.8%; Score 29.8; DB 8; Length 528;
      Best Local Similarity 36.9%; Pred. No. 29;
      Matches 24; Conservative 19; Mismatches 22; Indels 0; Gaps 0;

QY 13 AUUACGAGGCAUAGUCGACUCCUCCUCCUACACCAAGUUAUAUUGGUUUUAGC 72
Db 411 ATTATACAGGTATATATTGACTGCGTTTCTTGGACCAAAATACAAATTGAATTTAT 352

QY 73 AUAUG 77
Db 351 ACATG 347

CN553623
tae26g08.v1 Hydra EST Darmstadt I Hydra magnipapillata cDNA 5',
similar to TR.Q9VUZ2 Q9VUZ2 CG5656 PROTEIN. ;, mRNA sequence.
ACCESSION
  CN553623
VERSION
  CN553623.1 GI:46962927
KEYWORDS
  EST.
SOURCE
  Hydra magnipapillata
ORGANISM
  Eukaryota; Metazoa; Chnidaria; Hydrozoa; Hydroida; Anthomedusae;
  Hydridae; Hydra
  1 (bases 1 to 578)
REFERENCE
  Bode,H., Blumberg,B., Steele,R., Wigge,P., Gee,L., Nguyen,Q.,
  Martinez,D., Kibler,D., Hampson,S., Clifton,S., Pape,D., Marra,M.,

```

```

Hillier,L., Martin,J., Wylie,T., Dante,M., Theising,B., Bowers,Y.,
Gibbons,M., Rittter,E., Bennett,J., Ronko,I., Tsagarisvili,R.,
Maguire,D., Kennedy,S., Waterston,A. and Wilson,R.
WashU Hydra EST Project
Unpublished (2002)
Other ESTs: tae26g08.x1
Contact: Hans Bode
WashU Hydra EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@wustl.edu
Library was constructed by Corina Guder / GATC Konstanz, Germany
Library materials provided by Thomas Holstein / Molecular Cell
Biology, TUD, Darmstadt DNA sequencing by: Washington University
Genome Sequencing Center For information on obtaining a clone
Please contact: Hans Bode (hnbode@uci.edu)
Seq primer: -40UP
High quality sequence stop: 565.
FEATURES
      source
      Location/Qualifiers
          1..578
             /organism="Hydra magnipapillata"
             /mol_type="mRNA"
             /strain="sf-1 mutant of strain 105"
             /db_xref="taxon:6085"
             /lab_host="TransforMax EC100 (Epicentre), T1 Phage
             resistant electrocompetent cells"
             /clone_lib="Hydra EST Darmstadt I"
             /notes="Vector: pBluescript II SK (+); Site_1: NotI;
             Site_2: EcoRI"
ORIGIN
      Query Match      29.6%; Score 29.6; DB 7; Length 578;
      Best Local Similarity 40.8%; Pred. No. 34;
      Matches 31; Conservative 16; Mismatches 29; Indels 0; Gaps 0;

QY 21 AGGCAUAGUGGACUCCUCCUCCUCCUACACCAAGUUAUAUUGGUUUUAGCAUAGCCU 80
Db 453 AAGGATACGGGCATTTTGTGACCCCAATGAACAAAGTTGTGAATTCATCATTTGAGT 394

QY 81 UAGCGACAGCAAGCUU 96
Db 393 CAACGAGATCAAGTTT 378

RESULT 11
B838990/c
LOCUS
DEFINITION
  B838990 Gm01_01e04.F Gm01_AAPC_EC0RC Glycine max cold stressed_leaves
  Glycine max cDNA Clone Gm01_01e04, mRNA sequence.
ACCESSION
  B838990
VERSION
  B838990.1 GI:14205312
KEYWORDS
  EST.
SOURCE
  Glycine max (soybean)
ORGANISM
  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
  Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
  rosids; eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
  Glycine.
  1 (bases 1 to 617)
REFERENCE
  Singh,J.A., Robert,L.S., Lu,B., Zhu,L., De Moors,A., Couroux,P.,
  Harris,L.J., Hattori,J.I., Ouellet,T., Spratt,D. and Tinker,N.A.
  Expressed Sequence Tags from Cold-Stressed Glycine max (soybean)
  Leaves
  Unpublished (2001)
  Contact: Singh,J.A.
  Eastern Cereal and Oilseed Research Centre
  Agriculture and Agri-food Canada
  KW Neatby Bldg., Central Experimental Farm, Ottawa, Ontario, K1A
  0C6, Canada
  Tel: (613) 759-1662
  Fax: (613) 759-1701

```

```

Email: singhja@agr.gc.ca.
Location/Qualifiers
1. .617
/organism="Glycine max"
/mol_type="mRNA"
/cultivar="Maple Arrow"
/db_xref="taxon:3847"
/clone="Gm01.01e04"
/tissue_type="Leaves"
/dev_stage="15-day seedlings"
/clone_lib="Gm01_AAPC_ECORC_Glycine_max_cold_stressed_leav
es"
/notes="Vector: Bluescript SK-/XhoI-EcoRI; Site_1: EcoRI;
Site_2: XhoI; Plants were grown 12 days from seeds,
treated at 20C for 3 days, then leaves were collected.
Library was prepared using Unizap ZAP-cDNA synthesis kit
/ Packaged gigapack III Gold."

ORIGIN
Query Match 29.6%; Score 29.6; DB 4; Length 617;
Best Local Similarity 42.4%; Pred. No. 35;
Matches 36; Conservative 14; Mismatches 35; Indels 0; Gaps 0;

Qy 14 UUAUGCGAGCAUUGUGGACUCCGCUUCUUCUACACCAAGUUAUAAUUGUUUAGCA 73
Db 123 TGAGGCAAGCCAAATTTGACCCACCTCTCAATAAAATCAGTTAAATTTANGTTCCATCA 64

Qy 74 UAUUGCCUAGCGACGACGACUUCU 98
Db 63 TATGGGGAACAGAACCCCT 39

RESULT 12
CN623811
LOCUS 626 bp mRNA linear EST 12-MAY-2004
DEFINITION tae59d12.x1 Hydra EST Darmstadt I Hydra magnipapillata cDNA 3'
similar to TR:Q9VJZ2 Q9VJZ2 CG6565 PROTEIN.; mRNA sequence.
ACCESSION CN623811
VERSION 1 GI:47134888
KEYWORDS EST.
SOURCE Hydra magnipapillata
ORGANISM Hydra magnipapillata
Eukaryota; Metazoa;
Hydridae; Hydra.
REFERENCE 1 (bases 1 to 626)
Bode,H., Blumberg,B., Steele,R., Wigge,P., Gee,L., Nguyen,Q.,
Martinez,D., Kibler,D., Hampson,S., Clifton,S., Pape,D., Marra,M.,
Hillier,L., Martin,J., Wylie,T., Dante,M., Theising,B., Bowers,Y.,
Gibbons,M., Ritter,E., Bennett,J., Ronko,I., Tsagarishvili,R.,
Maguire,L., Kennedy,S., Waterston,R. and Wilson,R.
WashU Hydra EST Project
Unpublished (2002)
Contact: Hans Bode
WashU Hydra EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Library was constructed by Corina Guder / GATC Konstanz, Germany
Library materials provided by Thomas Holstein / Molecular Cell
Biology, TUD, Darmstadt DNA sequencing by: Washington University
Genome Sequencing Center For information on obtaining a clone
please contact: Hans Bode (hrobe@uci.edu)
Seq primer: degenerate primer
High quality sequence stop: 626.
Location/Qualifiers
1. .626
/organism="Hydra magnipapillata"
/mol_type="mRNA"
/strain="sf-1 mutant of strain 105"
/db_xref="taxon:6085"
/lab_host="TransformMax EC100 (Epicentre), T1 Phage

FEATURES
source
WashU Hydra EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Library materials provided by Corina Guder / GATC Konstanz, Germany
Library materials provided by Thomas Holstein / Molecular Cell
Biology, TUD, Darmstadt DNA sequencing by: Washington University
Genome Sequencing Center For information on obtaining a clone
please contact: Hans Bode (hrobe@uci.edu)
Seq primer: degenerate primer
High quality sequence stop: 626.
Location/Qualifiers
1. .626
/organism="Hydra magnipapillata"
/mol_type="mRNA"
/strain="sf-1 mutant of strain 105"
/db_xref="taxon:6085"
/lab_host="TransformMax EC100 (Epicentre), T1 Phage

```

```

resistant electrocompetent cells"
/clone_lib="Hydra EST Darmstadt I"
/notes="Vector: pBluescript II SK (+); Site_1: NotI;
Site_2: EcoRI"

ORIGIN
Query Match 29.6%; Score 29.6; DB 7; Length 626;
Best Local Similarity 40.8%; Pred. No. 35;
Matches 31; Conservative 16; Mismatches 29; Indels 0; Gaps 0;

Qy 21 AGGCAUUGUGGACUCCGCUUCUUCUACACCAAGUUAUAAUUGUUUAGCAUAGCCU 80
Db 377 AGGGATATGGCCTTTGTGACCAATGAAACAAAGTTGTGAAGTTCATCATTTGAGT 436

Qy 81 UAGCGACAGCAAGCUU 96
Db 437 CACAAGATCAAGTTT 452

RESULT 13
CN553289
LOCUS 717 bp mRNA linear EST 03-MAY-2004
DEFINITION tae26g08.x1 Hydra EST Darmstadt I Hydra magnipapillata cDNA 3'
similar to TR:Q9VJZ2 Q9VJZ2 CG6565 PROTEIN.; mRNA sequence.
ACCESSION CN553289
VERSION 1 GI:46962593
KEYWORDS EST.
SOURCE Hydra magnipapillata
ORGANISM Hydra magnipapillata
Eukaryota; Metazoa;
Hydridae; Hydra.
REFERENCE 1 (bases 1 to 717)
Bode,H., Blumberg,B., Steele,R., Wigge,P., Gee,L., Nguyen,Q.,
Martinez,D., Kibler,D., Hampson,S., Clifton,S., Pape,D., Marra,M.,
Hillier,L., Martin,J., Wylie,T., Dante,M., Theising,B., Bowers,Y.,
Gibbons,M., Ritter,E., Bennett,J., Ronko,I., Tsagarishvili,R.,
Maguire,L., Kennedy,S., Waterston,R. and Wilson,R.
WashU Hydra EST Project
Unpublished (2002)
Contact: Hans Bode
WashU Hydra EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Library was constructed by Corina Guder / GATC Konstanz, Germany
Library materials provided by Thomas Holstein / Molecular Cell
Biology, TUD, Darmstadt DNA sequencing by: Washington University
Genome Sequencing Center For information on obtaining a clone
please contact: Hans Bode (hrobe@uci.edu)
Seq primer: degenerate primer.
Location/Qualifiers
1. .717
/organism="Hydra magnipapillata"
/mol_type="mRNA"
/strain="sf-1 mutant of strain 105"
/db_xref="taxon:6085"
/lab_host="TransformMax EC100 (Epicentre), T1 Phage
resistant electrocompetent cells"
/clone_lib="Hydra EST Darmstadt I"
/notes="Vector: pBluescript II SK (+); Site_1: NotI;
Site_2: EcoRI"

ORIGIN
Query Match 29.6%; Score 29.6; DB 7; Length 717;
Best Local Similarity 40.8%; Pred. No. 36;
Matches 31; Conservative 16; Mismatches 29; Indels 0; Gaps 0;

Qy 21 AGGCAUUGUGGACUCCGCUUCUUCUACACCAAGUUAUAAUUGUUUAGCAUAGCCU 80
Db 466 AAGGATACGGGCACCTTTGTGACCAATGAAACAAAGTTGTGAAGTTCATCATTTGAGT 525

```

```

QY      81  URAGCGACGCAAGCTT 96
      |||||
Db      526  CAACGAGATCAAGTTT 541

RESULT 14
CN226782      744 bp  mRNA  linear  EST 09-APR-2004
LOCUS      RJB004H01.ab1 RJ-testis Gallus gallus cDNA 5', mRNA sequence.
DEFINITION  CN226782
ACCESSION  CN226782
VERSION    CN226782.1 GI:46330526
KEYWORDS  EST
SOURCE    Gallus gallus (chicken)
ORGANISM  Gallus gallus
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
          Phasianinae; Gallus.
REFERENCE  1 (bases 1 to 744)
          Savolainen, P., Fitzsimmons, C.J., Arvestad, L., Andersson, L. and
          Lundberg, J., Est analysis of brain and testis cDNA libraries from White Leghorn
          and Red Jungle Fowl
          Unpublished (2004)
JOURNAL
COMMENT    Department of Biotechnology
          Royal Institute of Technology, KTH
          SE-106 91 Stockholm, SWEDEN
          Tel: +46 (0)8 5537 8481
          Fax: +46 (0)8 5537 8335
          Email: Peter.Savolainen@biotech.kth.se
          Seq primer: M13 reverse primer.

FEATURES             Location/Qualifiers
     source           1..744
                     /organism="Gallus gallus"
                     /mol_type="mRNA"
                     /strain="Red junglefowl"
                     /db_xref="taxon:9031"
                     /sex="male"
                     /lab_host="ElectroMAX DH10B (Invitrogen)"
                     /clone_lib="RJTestis"
                     /note="Organ: testis; Vector: pSPORT-1; Site 1: Hind III;
                     Site 2: EcoRI; The cDNA libraries were created with the
                     Superscript Plasmid System (Invitrogen)."
```

ORIGIN

```

Query Match      29.6%; Score 29.6; DB 7; Length 744;
Best Local Similarity 55.8%; Pred. No. 36;
Matches 29; Conservative 9; Mismatches 14; Indels 0; Gaps 0;

QY      1  GGGAGUGGAGGAUAUCAGGACGAUAGUGCGACUCGUCUCCUCAAACC 52
      |||||
Db      491  GGGAGTTTAAGGCTTCATCGAGCAAAATGGGAGCTCCGTCCTCCATCGCACC 542

RESULT 15
CO421969      745 bp  mRNA  linear  EST 02-JUL-2004
LOCUS      GGEZHT1005A10.g HT1 Gallus gallus cDNA clone GGEZHT1005A10, mRNA
DEFINITION  sequence.
ACCESSION  CO421969
VERSION    CO421969.1 GI:49638217
KEYWORDS  EST
SOURCE    Gallus gallus (chicken)
ORGANISM  Gallus gallus
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
          Phasianinae; Gallus.
REFERENCE  1 (bases 1 to 745)
          Silva, C.S., Jorge, E.C., Patricio, M., Ledur, M.C. and Coutinho, L.L.
          Discovery of new genes expressed in the chicken pituitary and
          hypothalamus
          Unpublished (2004)
JOURNAL
COMMENT    Contact: Clarissa S. Silva
```

```

Laboratory of Animal Biotechnology, Dep. of Animal Production
ESALQ - University of Sao Paulo
Av. Padua Dias, 11, Piracicaba, SP, 13418-900, Brazil
Tel: 55 19 3429 4434
Fax: 55 19 3429 4285
Email: cssilva@esalq.usp.br and llcoutine@esalq.usp.br
PCR Primers
BACKWARD: T7.

FEATURES             Location/Qualifiers
     source           1..745
                     /organism="Gallus gallus"
                     /mol_type="mRNA"
                     /db_xref="taxon:9031"
                     /clone="GGEZHT1005A10"
                     /tissue_type="pituitary and hypothalamus"
                     /dev_stage="21 days old"
                     /lab_host="DH10B"
                     /clone_lib="HT1"
                     /notes="Vector: pSPORT1; Site 1: NotI; Site 2: SalI; This
                     cDNA library was constructed with the SuperScript Plasmid
                     System with Gateway Technology kit (Invitrogen), following a
                     manufacturer's protocols. Plasmid DNA was purified using a
                     modified alkaline lysis method. Sequencing reactions were
                     conducted using the kit Big Dye Terminator Cycle
                     Sequencing Ready Reaction (Applied Biosystems) according
                     to the manufacturer's recommendations. Clones were
                     sequenced by the 5' end with T7 primer. Sequencing
                     reactions were analyzed on ABI Prism 3100 Genetic Analyzer
                     (Applied Biosystems). The quality and clustering of the
                     ESTs were analyzed using the softwares Phred/Cap3. Only
                     EST sequences with Phred quality greater than 20 and at
                     least 150 bp were considered for clustering."
```

ORIGIN

```

Query Match      29.6%; Score 29.6; DB 7; Length 745;
Best Local Similarity 55.8%; Pred. No. 36;
Matches 29; Conservative 9; Mismatches 14; Indels 0; Gaps 0;

QY      1  GGGAGUGGAGGAUAUCAGGACGAUAGUGCGACUCGUCUCCUCAAACC 52
      |||||
Db      254  GGGAGTTTAAGGCTTCATCGAGCAAAATGGGAGCTCCGTCCTCCATCGCACC 305

Search completed: November 30, 2004, 12:52:13
Job time : 1709.11 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 30, 2004, 11:12:15 ; Search time 1093.89 Seconds
(without alignments)
4323.081 Million cell updates/sec

Title: US-09-529-397C-25
Perfect score: 100
Sequence: 1 gggaguggaggaaucaucg.....uagcagacgaagcuucgc 100

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 4526729 seqs, 23644849745 residues

Total number of hits satisfying chosen parameters: 9053458

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl.*

- 1: gb_ba.*
- 2: gb_htg.*
- 3: gb_in.*
- 4: gb_om.*
- 5: gb_ov.*
- 6: gb_pat.*
- 7: gb_ph.*
- 8: gb_pl.*
- 9: gb_pr.*
- 10: gb_ro.*
- 11: gb_sts.*
- 12: gb_sy.*
- 13: gb_uni.*
- 14: gb_vi.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	32.2	32.2	199415	10 AC084053	AC084053 Mus Muscu
2	31.2	31.2	201197	10 AC125279	AC125279 Mus muscu
3	30.8	30.8	187606	2 AC110847	AC110847 Rattus no
4	30.8	30.8	221981	2 AC103165	AC103165 Rattus no
5	30.8	30.8	231814	2 AC114165	AC114165 Rattus no
6	30.8	30.8	233823	2 AC110697	AC110697 Rattus no
7	30.8	30.8	238172	2 AC099144	AC099144 Rattus no
8	30.8	30.8	250740	2 AC129051	AC129051 Rattus no
9	30.6	30.6	748	6 CQ451733	CQ451733 Sequence
10	30.6	30.6	15776	6 CQ363795	CQ363795 Sequence
11	30.6	30.6	110000	1 AE017283_15	Continuation (16 o
12	30.4	30.4	217	4 AF522912	AF522912 Tachyglos
13	30.4	30.4	217	4 AF522914	AF522914 Tachyglos
14	30.4	30.4	217	4 AF522916	AF522916 Tachyglos
15	30.4	30.4	366	6 AR318058	AR318058 Sequence
16	30.4	30.4	3185	4 AY194920	AY194920 Tachyglos
17	30.4	30.4	46077	2 AC137289	AC137289 Rattus no
18	30.4	30.4	58143	2 AC137177	AC137177 Rattus no
19	30.4	30.4	207260	2 AC134220	AC134220 Rattus no

20	30.4	213033	2	AC131482	AC131482 Rattus no
21	30.4	218157	2	AC139588	AC139588 Rattus no
22	30.4	272400	2	AC110146	AC110146 Rattus no
23	30.4	283299	2	AC112576	AC112576 Rattus no
24	30.2	191004	2	CR536601	CR536601 Ornithorh
25	30.2	229522	2	AC109911	AC109911 Rattus no
26	30.2	235937	2	AC131223	AC131223 Rattus no
27	30.2	240755	2	AC095368	AC095368 Rattus no
28	30	213257	2	AC133102	AC133102 Mus muscu
29	29.8	4285	6	AR372457	AR372457 Sequence
30	29.8	4285	8	AF057708	AF057708 Populus b
31	29.8	184147	9	AC103805	AC103805 Homo sapi
32	29.8	191844	2	AC148836	AC148836 Pan trogl
33	29.8	202287	2	AC145887	AC145887 Pan trogl
34	29.8	215994	9	AC067941	AC067941 Homo sapi
35	29.8	223143	2	CR450730	CR450730 Danio rer
36	29.6	23393	2	AC018216	AC018216 Drosophil
37	29.6	50481	2	AC117541	AC117541 Mus muscu
38	29.6	79826	3	AC002443	AC002443 Drosophil
39	29.6	110000	2	AC110832_3	Continuation (4 of
40	29.6	110000	2	AC112373_04	Continuation (5 of
41	29.6	156806	3	AC093047	AC093047 Drosophil
42	29.6	182816	5	AC145913	AC145913 Gallus ga
43	29.6	192132	3	AC093440	AC093440 Drosophil
44	29.6	234627	2	AC106118	AC106118 Rattus no
45	29.6	237005	2	AC137343	AC137343 Rattus no

ALIGNMENTS

RESULT 1	AC084053	Mus Musculus Strain C57BL6/J	199415 bp	DNA	linear	ROD 05-SEP-2002
LOCUS	AC084053					
DEFINITION	AC084053					sequence.
ACCESSION	AC084053					
VERSION	AC084053.6					GI:22725947
KEYWORDS	HTG.					
SOURCE	Mus musculus					(house mouse)
ORGANISM	Mus musculus					
REFERENCE						
AUTHORS	Han, J., Montgomery, K.T., Grills, G., Chiu, D., Decker, J., Fusiina, M., Goltz, J., Haider, A., Hall, L., Ioshikhes, I.P., Lee, E., Long, J., Perera, A., Shim, C., Thomas, E. and Kucherlapati, R.					
TITLE	High Throughput Mouse Sequencing					
JOURNAL	Unpublished					
REFERENCE						
AUTHORS	2 (bases 1 to 199415)					
TITLE	Submitted (12-OCT-2000)					
JOURNAL	Department of Molecular Genetics, Albert Einstein College of Medicine Genome Center, 1300 Morris Park Ave., Bronx, NY 10461, USA					
REFERENCE						
AUTHORS	3 (bases 1 to 199415)					
TITLE	Submitted (29-JUL-2002)					
JOURNAL	Harvard Partners Center for Genetics and Genomics, Harvard Medical School, 65 Landsdowne St, Cambridge, MA 02139, USA					
REFERENCE						
AUTHORS	4 (bases 1 to 199415)					
TITLE	Submitted (05-SEP-2002)					
JOURNAL	Harvard Partners Center for Genetics and Genomics, Harvard Medical School, 65 Landsdowne St, Cambridge, MA 02139, USA					


```

repeat_region 23882..24118
/rpt_family="Lx4"
complement(24228..24641)
/rpt_family="Lx6"
complement(24821..25092)
/rpt_family="Lx3"
25183..25208
/rpt_family="TAAA)n"
25210..25277
/rpt_family="GAAA)n"
complement(25288..25661)
/rpt_family="MRC"
complement(26114..32348)
/rpt_family="LIF"

Query Match 32.2%; Score 32.2; DB 10; Length 199415;
Best Local Similarity 49.1%; Pred No. 8.5;
Matches 26; Conservative 14; Mismatches 13; Indels 0; Gaps 0;

QY 37 CGUCUCCUCAAACAGUUAUUAUGUUUUAUGCAUUGCUUAGCGACAG 89
Db 63221 CTTATTCCTTAAACACAGTATATAATCTTGTCATGATGATGTCTG 63273

RESULT 2
AC125279/c
LOCUS Mus musculus BAC clone RP23-433F5 from 8, complete sequence.
DEFINITION AC125279
ACCESSION AC125279.1 GI:21536173
VERSION HTG.
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 201197)
Trani, L. and Cotton, M.
The sequence of Mus musculus BAC clone RP23-433F5
Unpublished (2001)
Wilson, R.
Sequencing of Mus musculus
Unpublished (2001)
3 (bases 1 to 201197)
McPherson, J.D. and Waterston, R.H.
Direct Submission
Submitted (21-JUN-2002) Genome Sequencing Center, 4444 Forest Park
Parkway, St. Louis, MO 63108, USA
4 (bases 1 to 201197)
Wilson, R.
Direct Submission
Submitted (05-NOV-2003) Department of Genetics, Washington
University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA
----- Genome Center
Center: Washington University Genome Sequencing Center
Center code: WUGSC
Web site: http://genome.wustl.edu
Contact: submissions@wustl.edu
----- Summary Statistics
Center project name: M_BA0433P05
-----

```

NOTICE: This sequence may not represent the entire insert of this clone. It may be shorter because we only sequence overlapping clone sections once, or longer because we provide a small overlap between neighboring data submissions.

This sequence was finished as follows unless otherwise noted: all regions were double stranded, sequenced with an alternate chemistry, or covered by high quality data (i.e., phred quality >= 30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by sequence from more than one subclone; and the assembly was confirmed by

restriction digest.

MAPPING INFORMATION:
Mapping information for this clone was provided by Dr. Wes Warren, Department of Genetics, Washington University, St. Louis MO. For additional information about the map position of this sequence, see <http://genome.wustl.edu>

SOURCE INFORMATION:
The RPCI-23 BAC Library has been constructed by Kazutoyo Osegawa and Minako Tatenio in the laboratory of Pieter de Jong (<http://www.chori.org>) from female C57BL/6J mouse kidney and/or brain genomic DNA. The clone and detailed information can be obtained from Research Genetics, Inc. (<http://www.resgen.com>) or Pieter de Jong and coworkers at <http://www.chori.org>

NEIGHBORING SEQUENCE INFORMATION:

This sequence is the entire insert of the clone.

FEATURES	Location/Qualifiers
source	1..201197 /organism="Mus musculus" /mol_type="genomic DNA" /db_xref="taxon:10090" /chromosome="8" /map="8"
repeat_region	/clone="RP23-433F5" /clone_lib="RPCI-23" 171..557 /rpt_family="MaLR"
repeat_region	558..1352 /rpt_family="MaLR"
repeat_region	1353..1499 /rpt_family="Alu"
repeat_region	1500..1886 /rpt_family="MaLR"
repeat_region	1887..2101 /rpt_family="MaLR"
repeat_region	2103..2485 /rpt_family="L1"
repeat_region	2752..2918 /rpt_family="Alu"
repeat_region	2916..3337 /rpt_family="RMR6B"
repeat_region	5516..5712 /rpt_family="MaLR"
repeat_region	6071..6162 /rpt_family="ERVK"
repeat_region	6163..6556 /rpt_family="MaLR"
repeat_region	6557..6980 /rpt_family="ERVK"
repeat_region	7137..7220 /rpt_family="MIR"
repeat_region	7970..8262 /rpt_family="L1"
repeat_region	8734..9125 /rpt_family="L1"
repeat_region	9194..10473 /rpt_family="L1"
repeat_region	10485..10619 /rpt_family="MER1_type"
repeat_region	10573..10940 /rpt_family="ERVK"
repeat_region	10673..11051 /rpt_family="RMR17C"
repeat_region	11200..12140 /rpt_family="L1"
repeat_region	12674..12714 /rpt_family="L1"
repeat_region	12715..12907 /rpt_family="B2"
repeat_region	12908..13742 /rpt_family="L1"

```

repeat_region 14760..15436
/rpt_family="L1"
repeat_region 16028..16131
/rpt_family="MaLR"
repeat_region 17836..18263
/rpt_family="L1"
repeat_region 18352..18653
/rpt_family="ERVK"
repeat_region 18655..19078
/rpt_family="ERVK"
repeat_region 19375..19942
/rpt_family="L1"
repeat_region 21030..21117
/rpt_family="MaLR"
repeat_region 22308..22444
/rpt_family="MIR"
repeat_region 22775..22988
/rpt_family="MER1_type"
repeat_region 22991..23088
/rpt_family="L1"
repeat_region 23274..23681
/rpt_family="MaLR"
repeat_region 24784..24971
/rpt_family="B2"
repeat_region 25314..25486
/rpt_family="MaLR"
repeat_region 26145..26223
/rpt_family="RAL_RN"
repeat_region 26473..26619
/rpt_family="Alu"
repeat_region 26817..27001
/rpt_family="B2"
tRNA complement(26924..26996)
/product="trna-Ser"
/notes="Likely pseudogene (HMM Sc=39.59 / Sec struct
Sc=-11.21)"
repeat_region 27016..27079
/rpt_family="Alu"
repeat_region 28465..28604
/rpt_family="Alu"
repeat_region 28818..29133
/rpt_family="MaLR"
repeat_region 29251..29389
/rpt_family="MIR"
repeat_region 29546..29687
/rpt_family="MaLR"
repeat_region 30593..30737
/rpt_family="L2"
repeat_region 32073..32437
/rpt_family="MaLR"
repeat_region 33137..33276
/rpt_family="Alu"
repeat_region 33402..33547
/rpt_family="Alu"
repeat_region 35207..35290
/rpt_family="MIR"
repeat_region 35653..35830
/rpt_family="MaLR"
repeat_region 35831..36039
/rpt_family="B2"
repeat_region 36040..36232
/rpt_family="MaLR"
repeat_region 36324..36549
/rpt_family="B4"
repeat_region 36705..36788
/rpt_family="B4"
repeat_region 36795..36891
/rpt_family="ERVL"
repeat_region 36862..37099
/rpt_family="MaLR"
repeat_region 39693..39806
/rpt_family="MER1_type"
repeat_region 40903..41102

```

```

repeat_region 41131..41296
/rpt_family="MER2_type"
repeat_region 41519..41626
/rpt_family="L2"
repeat_region 42585..42730
/rpt_family="Alu"

Query Match 31.2%; Score 31.2; DB 10; Length 201197;
Best Local Similarity 32.6%; Pred. No. 19;
Matches 30; Conservative 24; Mismatches 38; Indels 0; Gaps 0;

QY 7 GGAGGAUUGCAUGCGCAUUGCGACUCCGCUUCUACCAACCAAGUUAUUAUUGU 66
Db 2984 CGAGCTTTCATCCAGCATCTGATCTCGAGTCTTCATTGATAAAATCAACATGAG 2925

QY 67 UUUAGCAUUGCCUUAGCGACGACGACGCUUCU 98
Db 2924 TTTTGTGTTTGTGTTTTCGAGACCGAGGTTCT 2893

RESULT 3
AC110847 187606 bp DNA linear HTG 15-NOV-2002
LOCUS Rattus norvegicus clone CH230-42M10, *** SEQUENCING IN PROGRESS
DEFINITION *** 13 unordered pieces.
ACCESSION AC110847
VERSION AC110847.6 GI:25006792
KEYWORDS HTG; HTGS_PHASE1; HTGS_DRAFT; HTGS_ENRICHED.
SOURCE Rattus norvegicus
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE 1 (bases 1 to 187606)
AUTHORS Murny,D.,Marie., Metzker,M.,Lee., Abramson,S., Adams,C., Alder,J.,
Allen,C., Allen,H., Alsbrooks,S., Amin,A., Arguiano,D.,
Anyalebechi,V., Aoyagi,A., Ayodeji,M., Baca,E., Baden,H.,
Baldwin,D., Bandaranaike,D., Barber,M., Barnstead,M., Benahmed,F.,
Biswal,K., Blair,J., Blankenburg,K., Blyth,P., Brown,M.,
Bryant,N., Buhay,C., Burch,P., Burrell,K., Calderon,E.,
Cardenas,V., Carter,K., Cavazos,I., Ceasar,H., Center,A.,
Chacko,J., Chavez,D., Chen,G., Chen,R., Chen,Y., Chen,Z., Chu,J.,
Cleveland,C., Cockrell,R., Cox,C., Coyle,M., Cree,A., D'Souza,L.,
Davila,M.L., Davis,C., Davy-Carroll,L., De Anda,C., Dederich,D.,
Delgado,O., Denison,S., Deramo,C., Ding,Y., Dinh,H., Divya,K.,
Draper,H., Dugan-Rocha,S., Dunn,A., Durbin,K., Duval,B., Baves,K.,
Egan,A., Escotto,M., Eugene,C., Evans,C.A., Faller,T., Pan,G.,
Fernandez,S., Finley,M., Flagg,N., Forbes,L., Foster,M., Foster,P.,
Fraser,C.M., Gabisi,A., Ganta,R., Garcia,A., Garner,T., Garza,M.,
Gebregorgis,E., Geer,K., Gill,R., Grady,M., Guerra,W., Guevara,W.,
Gunaratne,P., Haaland,W., Hamil,C., Hamilton,C., Hamilton,K.,
Harvey,Y., Havlak,P., Hawes,A., Henderson,N., Hernandez,J.,
Hernandez,R., Hines,S., Hladun,S.L., Hodgson,A., Hogues,M.,
Hollins,B., Howells,S., Hulyk,S., Hume,J., Idlebird,D., Jackson,A.,
Jackson,L., Jacob,L., Jiang,H., Johnson,B., Johnson,R., Jolivet,A.,
Karpthy,S., Kelly,S., Kelly,S., Khan,Z., King,L., Kovar,C.,
Kowis,C., Kraft,C.L., Lebow,H., Levan,J., Lewis,L., Li,Z., Liu,J.,
Liu,J., Liu,W., Liu,Y., London,P., Longacre,S., Lopez,J.,
Lorensuhewa,L., Loulsegod,H., Lozado,R.J., Lu,X., Ma,J.,
Maheshwari,M., Mahindartne,M., Mahmoud,M., Malloy,K., Mangum,A.,
Mangum,B., Mapua,P., Martin,K., Martin,R., Martinez,E.,
Mawhney,S., McLeod,M.P., McNeill,T.Z., Meenen,E.,
Milosavljevic,A., Miner,G., Minja,E., Montemayor,J., Moore,S.,
Morgan,M., Morris,K., Morris,S., Munidasa,M., Murphy,M., Nail,L.,
Nankervis,C., Neal,D., Newton,N., Nguyen,N., Norris,S.,
Nwankweli,O., Okwuonu,G., Olarnpusagoon,A., Pal,S., Parks,K.,
Pasternak,S., Paul,H., Perez,A., Perez,L., Pfannkuch,C.,
Plopper,F., Poindexter,A., Popovic,D., Primus,E., Pu,L.-L.,
Puazo,M., Quiroz,J., Rachlin,E., Reeves,K., Regier,M.A., Reigh,R.,
Reilly,B., Reilly,M., Ren,Y., Reuter,M., Richards,S., Riggs,F.,
Rives,C., Rodkey,T., Rojas,A., Rose,M., Rose,R., Ruiz,S.J.,
Sanders,W., Savary,G., Scherer,S., Scott,G., Shatsman,S., Shen,H.,

```


Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.

1 (bases 1 to 233823)
 Muzny, D. Marie, Metzker, M. Lee, Abramson, S., Adams, C., Alder, J., Allen, C., Allen, H., Alsbrooks, S., Amin, A., Anguiano, D., Anyalebechi, V., Aoyagi, A., Ayodeji, M., Baca, E., Baden, H., Baldwin, D., Bandaranaike, D., Barber, M., Barnstead, M., Benahmed, F., Biswal, K., Blair, J., Blankenburg, K., Blythe, P., Brown, M., Bryant, N., Buhay, C., Burch, P., Burrell, K., Calderon, E., Cardenas, V., Carter, K., Cavazos, I., Cesar, H., Center, A., Chacko, J., Chavez, D., Chen, G., Chen, R., Chen, Y., Chen, Z., Chu, J., Cleveland, C., Cockrell, R., Cox, C., Coyly, M., Cree, A., D'Souza, L., Davila, M., Davis, C., Davy-Carroll, L., De Anda, C., Dederich, D., Delgado, O., Denson, S., Derano, C., Ding, Y., Dinh, H., Divya, K., Draper, H., Dugan-Rocha, S., Dunn, A., Durbin, K., Duval, B., Eaves, K., Egan, A., Escotto, M., Eugene, C., Evans, C.A., Falls, T., Fan, G., Fernandez, S., Finley, M., Flagg, N., Forbes, L., Foster, M., Foster, P., Fraser, C.M., Gabisi, A., Ganta, R., Garcia, A., Garner, T., Garza, M., Gbrageorgis, E., Geer, K., Gill, R., Grady, M., Guerra, W., Guevara, W., Gunaratne, P., Haaland, W., Hamill, C., Hamilton, C., Hamilton, K., Harvey, Y., Havlak, P., Hayes, A., Henderson, N., Hernandez, J., Hernandez, R., Hines, S., Hladun, S.L., Hodgson, A., Hogues, M., Hollins, B., Howells, S., Hulyk, S., Hume, J., Idlebird, D., Jackson, A., Jackson, L., Jacob, L., Jiang, H., Johnson, B., Johnson, R., Jolivet, A., Karpach, S., Kelly, S., Kelly, S., Khan, Z., King, L., Kovar, C., Kowis, C., Kraft, C.L., Lebow, H., Levan, J., Lewis, L., Li, Z., Liu, J., Liu, J., Liu, W., Liu, Y., London, P., Longacre, S., Lopez, J., Loresueta, L., Loulsged, H., Lozano, R., Lu, X., Ma, J., Maheshwari, M., Mahindaratne, M., Mahmoud, M., Malloy, K., Mangum, A., Mangum, B., Mapua, P., Martin, K., Martin, R., Martinez, E., Mawhney, S., McLeod, M.P., McNeill, T.Z., Meenen, E., Milosavljevic, A., Miner, G., Minja, E., Montemayor, J., Moore, S., Morgan, M., Morris, K., Morris, S., Munidasa, M., Murphy, M., Nair, L., Nankervis, C., Neal, D., Newton, N., Nguyen, N., Norris, S., Nwackelme, O., Okunolu, G., Olarnpunsagoon, A., Pal, S., Parks, K., Pasternak, S., Paul, H., Perez, A., Perez, L., Pfannkuch, C., Pioppier, F., Poindexter, A., Popovic, D., Primus, E., Pu, L.-L., Puazo, M., Quiroz, J., Rachlin, E., Reeves, K., Regier, M.A., Reigh, R., Reilly, B., Reilly, M., Ren, Y., Reuter, M., Richards, S., Riggs, F., Rives, C., Rodkey, T., Rojas, A., Rose, M., Rose, R., Ruiz, S.J., Sanders, W., Savary, G., Scherer, S., Scott, G., Shatsman, S., Shen, H., Shetty, J., Shvartsbeyn, A., Sisson, I., Sitter, C.D., Smajls, D., Sneed, A., Sodergren, E., Song, X.-Z., Sorelle, R., Sosa, J., Steimle, M., Strong, R., Sutton, A., Svatek, A., Tabor, P., Taylor, C., Taylor, T., Thomas, N., Thomas, S., Tingey, A., Trejos, Z., Usmann, K., Valas, R., Vera, V., Villalana, D., Waldron, L., Walker, B., Wang, J., Wang, Q., Wang, S., Warren, J., Warren, R., Wei, X., White, F., Williams, G., Willson, R., Wleczky, R., Wooden, H., Worley, K., Wright, D., Wright, R., Wu, J., Yakub, S., Yen, J., Yoon, L., Yoon, V., Yu, F., Zhang, J., Zhou, J., Zhou, X., Zhao, S., Dunn, D., von Niederhausern, A., Weis, R., Smith, D.R., Holt, R.A., Smith, H.O., Weinstock, G. and Gibbs, R.A.

Direct Submission
 Unpublished
 2 (bases 1 to 233823)
 Worley, K.C.
 Direct Submission
 Submitted (15-FEB-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
 3 (bases 1 to 233823)
 Rat Genome Sequencing Consortium.
 Direct Submission
 Submitted (23-NOV-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
 On Nov 23, 2002 this sequence version replaced gi:23267238.
 The sequence in this assembly is a combination of BAC based reads and whole genome shotgun sequencing reads assembled using Atlas (http://www.hgsc.bcm.tmc.edu/projects/rat/). Each contig described in the feature table below represents a scaffold in the atlas assembly (a 'contig-scaffold'). Within each contig-scaffold, individual sequence contigs are ordered and oriented, and separated

by sized gaps filled with Ns to the estimated size. The sequence may extend beyond the ends of the clone and there may be sequence contigs within a contig-scaffold that consist entirely of whole genome shotgun sequence reads. Both end sequences and whole genome shotgun sequence only contigs will be indicated in the feature table.

----- Genome Center
 Center: Baylor College of Medicine
 Center code: BCM
 Web site: http://www.hgsc.bcm.tmc.edu/
 Contact: hgsc-help@bcm.tmc.edu
 ----- Project Information
 Center project name: GRXR
 Center clone name: CH230-43H7
 ----- Summary Statistics
 Assembly program: Phrap; version 0.990329
 Consensus quality: 212738 bases at least Q40
 Consensus quality: 215401 bases at least Q30
 Consensus quality: 217067 bases at least Q20
 Estimated insert size: 219523; sum-of-contigs estimation
 Quality coverage: 6x in Q20 bases; sum-of-contigs estimation

 * NOTE: Estimated insert size may differ from sequence length
 * (see http://www.hgsc.bcm.tmc.edu/docs/Genbank_draft_data.html).
 * NOTE: This is a 'working draft' sequence. It currently
 * consists of 1 contigs. Gaps between the contigs
 * are represented as runs of N. The order of the pieces
 * is believed to be correct as given, however the sizes
 * of the gaps between them are based on estimates that have
 * provided by the submittor
 * This sequence will be replaced
 * by the finished sequence as soon as it is available and
 * the accession number will be preserved.
 * 1 233823: contig of 233823 bp in length.

FEATURES

source

1. 233823
 /organism="Rattus norvegicus"
 /mol_type="genomic DNA"
 /db_xref="taxon:10116"
 /clone="CH230-43H7"

misc_feature

1. 1276
 /note="wgs_end_extension
 clone_end:T7"

misc_feature

1327..2821
 /note="wgs_end_extension
 clone_end:T7"

misc_feature

7344..8215
 /note="clone_boundary
 clone_end:T7
 site:ECORI

misc_feature

end sequence:BH264888"
 85851..88514
 /note="wgs_contig"

misc_feature

complement(232161..232332)
 /note="clone_boundary
 clone_end:Sp6
 site:ECORI
 end_sequence:BH264890"

ORIGIN

Query Match 30.8%; Score 30.8; DB 2; Length 233823;
 Best Local Similarity 34.7%; Pred. No. 26;
 Matches 34; Conservative 22; Mismatches 42; Indels 0; Gaps 0;

QY 2 GGAGUGGAGGAUUCAGUGGAGCAUUGCGUCCUUCUUAACACCAUUAUAAA 61

DB 230212 GTAGAGAGATATATAGAGTTATTTATCACTGTTTTTCTAAAGTCATTATAT 230271

QY 62 UUGGUUUUAGCAUUGCCUUAUGGACGACGACGACUUCUG 99

DB 230272 TTAGTTTTCCTAGGTCTTGGGCCATCAAGTTTCAG 230309

Submitted (10-MAY-2003) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA

On May 10, 2003 this sequence version replaced gi:23264509.

The sequence in this assembly is a combination of BAC based reads and whole genome shotgun sequencing reads assembled using Atlas (http://www.hgsc.bcm.tmc.edu/projects/rat/). Each contig described in the feature table below represents a scaffold in the Atlas assembly (a 'contig-scaffold'). Within each contig-scaffold, individual sequence contigs are ordered and oriented, and separated by sized gaps filled with Ns to the estimated size. The sequence may extend beyond the ends of the clone and there may be sequence contigs within a contig-scaffold that consist entirely of whole genome shotgun sequence reads. Both end sequences and whole genome shotgun sequence only contigs will be indicated in the feature table.

----- Genome Center
Center: Baylor College of Medicine
Center code: BCM
Web site: http://www.hgsc.bcm.tmc.edu/
Contact: hgsc-help@bcm.tmc.edu

----- Project Information
Center project name: CH230-68F7
Center clone name: CH230-68F7
----- Summary Statistics
Assembly program: Atlas 3.0;
Consensus quality: 220106 bases at least Q40
Consensus quality: 222963 bases at least Q30
Consensus quality: 224727 bases at least Q20
Estimated insert size: 230633; sum-of-contigs estimation
Quality coverage: 7x in Q20 bases; sum-of-contigs estimation

* NOTE: Estimated insert size may differ from sequence length
* (see http://www.hgsc.bcm.tmc.edu/docs/genbank_draft_data.html).
* NOTE: This is a 'working draft' sequence. It currently
* consists of 1 contigs. Gaps between the contigs
* are represented as runs of N. The order of the pieces
* is believed to be correct as given, however the sizes
* of the gaps between them are based on estimates that have
* provided by the submitter.
* This sequence will be replaced
* by the finished sequence as soon as it is available and
* the accession number will be preserved.

* 1 238172: contig of 238172 bp in length.
* Location/Qualifiers
1..238172
/organism="Rattus norvegicus"
/mol_type="genomic DNA"
/db_xref="taxon:10116"
/clone="CH230-68F7"
1..1721
/note="wgs end extension
clone_end:Sp6"
8345..8845
/note="clone boundary
clone_end:Sp6
site:EcoRI
end_sequence:BH351992"
234541..234906
/note="clone boundary
clone_end:T7"
site:EcoRI
end_sequence:BH351956"
236172..238172
/note="wgs end extension
clone_end:T7"

FEATURES
source
misc_feature
misc_feature
misc_feature
misc_feature

ORIGIN
Query Match 30.8%; Score 30.8; DB 2; Length 238172;
Best Local Similarity 43.1%; Pred. No. 26;
Matches 25; Conservative 16; Mismatches 17; Indels 0; Gaps 0;
23 GCAUAGUCGACGCGGCUUCCUCAAACCAAGUAAUAAUUGGUUAGCAUAGCCU 80

RESULT 10	CQ363795	15776 bp	DNA	linear	PAT 23-JAN-2004
LOCUS	Sequence 78 from Patent WO0181581.				
DEFINITION	CQ363795				
ACCESSION	CQ363795				
KEYWORDS	CQ363795.1	GI:41300489			
SOURCE	Propionibacterium acnes				
ORGANISM	Propionibacterium acnes				
REFERENCE	Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales; Propionibacteriaceae; Propionibacteriaceae; Propionibacterium.				
AUTHORS	1 Skeiky,Y.A., Persing,D.H., Mitcham,J.L., Wang,S.S., Bhatia,A., L'Maisonneuve,J.F., Zhang,Y., Jen,S., and Carter,D.				
TITLE	Compositions and methods for the therapy and diagnosis of acne vulgaris				
JOURNAL	Patent: WO 0181581-A 78 01-NOV-2001;				
FEATURES	CORIXA CORPORATION (US)				
source	Location/Qualifiers				
	1..15776				
	/organism="Propionibacterium acnes"				
	/mol_type="unassigned DNA"				
	/db_xref="taxon:1747"				

RESULT 12	
AF522912/c	
LOCUS	AF522912
DEFINITION	Tachyglossus aculeatus clone Tag7 type I interferon gene, partial cds.
ACCESSION	AF522912
VERSION	AF522912.1 GI:27451581
KEYWORDS	.
SOURCE	Tachyglossus aculeatus (Australian echidna)
ORGANISM	Tachyglossus aculeatus
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
	Mammalia; Monotremata; Tachyglorissidae; Tachyglossus.
REFERENCE	1 (bases 1 to 217)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 30, 2004, 11:12:11 ; Search time 232.222 Seconds
(without alignments)
2260.516 Million cell updates/sec

Title: US-09-529-397C-25

Perfect score: 100

Sequence: 1 gggaguggaggaaucaucg.....uagcagcagaagcuucguc 100

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 4134886 seqs, 2624710521 residues

Total number of hits satisfying chosen parameters: 8269772

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

N_Geneseq_23Sep04:*
1: Geneseqn1980s:*
2: Geneseqn1990s:*
3: Geneseqn2000s:*
4: Geneseqn2001as:*
5: Geneseqn2001bs:*
6: Geneseqn2002as:*
7: Geneseqn2002bs:*
8: Geneseqn2003as:*
9: Geneseqn2003bs:*
10: Geneseqn2003cs:*
11: Geneseqn2003ds:*
12: Geneseqn2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	100	100.0	100	3	Aaz99048	RNA aptam
2	100	100.0	100	12	ADJ10063	Synthetic
3	100	100.0	100	12	ADJ10064	Synthetic
4	100	100.0	200	12	ADJ10065	Synthetic
5	90	90.0	90	3	Aaz99050	RNA aptam
6	84.4	84.4	98	12	ADJ10053	RNA aptam
7	80	80.0	80	3	Aaz99051	RNA aptam
8	50.6	50.6	147	12	ADJ10066	Synthetic
9	45	45.0	45	3	Aaz99076	Ras target
10	30.6	30.6	748	3	Aaz75113	Human ORF
11	30.6	30.6	748	6	ABN24508	Human ORF
12	30.6	30.6	15776	8	Aaz59583	Propionib
13	30.6	30.6	15776	8	ACF64512	Propionib
14	30.4	30.4	366	9	ADA29321	DNA encod
15	30	30.0	98	3	Aaz99049	RNA aptam
16	29.8	29.8	4192	3	Aaz75942	Poplar fl
17	29.8	29.8	4285	4	AAF5391	Nucleotid
18	29.8	29.8	4285	6	ABK8484	Poplar pr
19	29.8	29.8	4285	9	ACA62517	Poplar ho
20	29	29.0	29	3	Aaz99084	Ras target
21	29	29.0	29	12	ADJ10055	Synthetic

c 22 28.8 28.8 675 8 ACA52761
c 23 28.6 28.6 2000 6 ABZ15103 Arabidops
c 24 28.2 28.2 1161 5 ABV24321 Human pro
c 25 28.2 28.2 1665 2 AAX58401 Vicia sat
c 26 28 28.0 29 12 ADJ10058
c 27 28 28.0 29 12 ADJ10057
c 28 28 28.0 29 12 ADJ10056
c 29 28 28.0 110000 6 ABX08336 01
c 30 28 28.0 110000 12 ADJ25985 01
c 31 28 28.0 110000 12 ADN97989 01
c 32 28 28.0 110000 12 ADOS0281 01
c 33 27.6 27.6 732 4 AAI94947
c 34 27.6 27.6 732 8 ABT42823
c 35 27.4 27.4 3791 2 AAT63575
c 36 27 27.0 27 3 AAZ99087
c 37 27 27.0 29 12 ADJ10059
c 38 27 27.0 208 3 AAC17425
c 39 27 27.0 522 3 AAA69206
c 40 27 27.0 56506 3 AAA69168
c 41 26.8 26.8 415 3 AAC21986
c 42 26.8 26.8 1116 5 AAH51835
c 43 26.8 26.8 1116 12 ADA44700
c 44 26.6 26.6 48995 9 ADA02579
c 45 26.6 26.6 48995 10 ADB72317

ALIGNMENTS

RESULT 1

Aaz99048
ID Aaz99048 standard; RNA; 100 BP.

XX AC Aaz99048;

XX DT 21-JUN-2000 (first entry)

XX DE RNA aptamer #25 for binding Ras target protein.

XX KW Ras target protein; malignant tumour; signal transduction regulation;
XX KW cell proliferation; cell differentiation; aptamer; inflammation; ss.

XX OS Homo sapiens.

XX PN WO200009684-A1.

XX PD 24-FEB-2000.

XX PF 13-AUG-1999; 99WO-JP004399.

XX PR 14-AUG-1998; 98JP-00242596.

XX PR 24-NOV-1998; 98JP-00333284.

XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.

XX Yokoyama S, Hirao I, Sakamoto K;

XX WPI; 2000-224330/19.

XX Nucleic acid e.g. RNA aptamer capable of binding specifically to Ras
XX target protein like Raf-1, useful in drug compositions to treat and
XX diagnose malignant tumors and inflammation.

XX Claim 6; Page 41; 59pp; Japanese.

XX The invention relates to novel nucleic acids which bind specifically to
XX the target protein of Ras, e.g. Raf-1. RNA aptamer (AAZ99048-239051)
XX based on these sequences are useful in the treatment and diagnosis of
XX malignant tumors and inflammation. The nucleic acids can be used to
XX formulate medicinal compositions that are useful in the treatment of
XX malignant tumors and inflammation and for disease diagnosis by binding
XX specifically to Ras target protein and regulating transmission of signal
XX causing proliferation or differentiation of cells

```
XX SQ Sequence 100 BP; 25 A; 22 C; 24 G; 0 T; 29 U; 0 Other;
Query Match 100.0%; Score 100; DB 3; Length 100;
Best Local Similarity 100.0%; Pred. No. 2.4e-25;
Matches 100; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGAGUGAGGAAUUCAGCAGGCAUAUGUGGACUCCGUCUCCUUAACCAAGUUAUA 60
DB 1 GGGAGUGAGGAAUUCAGCAGGCAUAUGUGGACUCCGUCUCCUUAACCAAGUUAUA 60
QY 61 AUUGUUUUAAGCAUAGCCUAGCGACAGCAAGCUUCG 100
DB 61 AUUGUUUUAAGCAUAGCCUAGCGACAGCAAGCUUCG 100

RESULT 2
ADJ10063
ID ADJ10063 standard; DNA; 100 BP.
XX
AC ADJ10063;
XX
DT 17-JUN-2004 (first entry)
XX
DE Synthetic RNA 9A (100-mer).
XX
KW ss; unnatural base; 5'-substituted-2-oxo(1H) - pyridin-3-yl;
KW photoreactive group; biotin; fluorescent molecule;
KW 6-substituted-2-aminopurin-9-yl; aptamer; gene therapy.
XX
OS Synthetic.
XX
PN WO2004007713-A1.
XX
PD 22-JAN-2004.
XX
PF 28-FEB-2003; 2003WO-JP002342.
XX
PR 17-JUL-2002; 2002JP-00208568.
XX
PA (RIKE ) RIKEN KK.
PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
PA (ADSC-) CENT ADVANCED SCI & TECHNOLOGY INCUBATIO.
XX
PI Hirao I, Yokoyama S, Hirao M, Mitsui T;
XX
DR WPI; 2004-122944/12.
XX
PS Nucleosides or nucleotides comprising novel base particularly 5-
substituted-2-oxo(1H)-pyridin-3-yl group as base, useful in developing
PT functional nucleic acids as reagents or therapeutics in treating
PT diseases.
XX
XX Disclosure; Fig 10; 78pp; Japanese.
XX
XX This invention relates to nucleosides or nucleotides that a novel
XX unnatural base, namely the 5'-substituted-2-oxo(1H) - pyridin-3-yl group
XX as a base. Specifically, it refers to nucleic acid molecules integrated
XX with a base substituted at the 5-position with either a photoreactive
XX group (e.g. iodine or bromine), an alkenyl, alkynyl or amino group,
XX biotin or a derivative thereof or a fluorescent molecule selected from
XX fluorescein, 6-carboxyfluorescein, tetramethyl-7-carboxyrhodamine or
XX derivatives thereof. The present invention describes preparing nucleic
XX acids by carrying out transcription, replication or reverse transcription
XX with a nucleic acid containing a 6-substituted-2-aminopurin-9-yl group as
XX base which is applied as template for the integration of any of the
XX sequence is a synthetic RNA 9A aptamer (100-mer) given in an

CC exemplification of the invention.
XX
SQ Sequence 100 BP; 25 A; 22 C; 24 G; 0 T; 29 U; 0 Other;
Query Match 100.0%; Score 100; DB 12; Length 100;
Best Local Similarity 100.0%; Pred. No. 2.4e-25;
Matches 100; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGAGUGAGGAAUUCAGCAGGCAUAUGUGGACUCCGUCUCCUUAACCAAGUUAUA 60
DB 1 GGGAGUGAGGAAUUCAGCAGGCAUAUGUGGACUCCGUCUCCUUAACCAAGUUAUA 60
QY 61 AUUGUUUUAAGCAUAGCCUAGCGACAGCAAGCUUCG 100
DB 61 AUUGUUUUAAGCAUAGCCUAGCGACAGCAAGCUUCG 100

RESULT 3
ADJ10064
ID ADJ10064 standard; DNA; 100 BP.
XX
AC ADJ10064;
XX
DT 17-JUN-2004 (first entry)
XX
DE Synthetic RNA 9A (51y87) aptamer (100-mer).
XX
KW ss; unnatural base; 5'-substituted-2-oxo(1H) - pyridin-3-yl;
KW photoreactive group; biotin; fluorescent molecule;
KW 6-substituted-2-aminopurin-9-yl; aptamer; gene therapy.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 87
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 51y"
XX
PN WO2004007713-A1.
XX
PD 22-JAN-2004.
XX
PF 28-FEB-2003; 2003WO-JP002342.
XX
PR 17-JUL-2002; 2002JP-00208568.
XX
PA (RIKE ) RIKEN KK.
PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
PA (ADSC-) CENT ADVANCED SCI & TECHNOLOGY INCUBATIO.
XX
PI Hirao I, Yokoyama S, Hirao M, Mitsui T;
XX
DR WPI; 2004-122944/12.
XX
PS Nucleosides or nucleotides comprising novel base particularly 5-
substituted-2-oxo(1H)-pyridin-3-yl group as base, useful in developing
PT functional nucleic acids as reagents or therapeutics in treating
PT diseases.
XX
XX Disclosure; Fig 10; 78pp; Japanese.
XX
XX This invention relates to nucleosides or nucleotides that a novel
XX unnatural base, namely the 5'-substituted-2-oxo(1H) - pyridin-3-yl group
XX as a base. Specifically, it refers to nucleic acid molecules integrated
XX with a base substituted at the 5-position with either a photoreactive
XX group (e.g. iodine or bromine), an alkenyl, alkynyl or amino group,
XX biotin or a derivative thereof or a fluorescent molecule selected from
XX fluorescein, 6-carboxyfluorescein, tetramethyl-7-carboxyrhodamine or
XX derivatives thereof. The present invention describes preparing nucleic
XX acids by carrying out transcription, replication or reverse transcription
XX with a nucleic acid containing a 6-substituted-2-aminopurin-9-yl group as
XX base which is applied as template for the integration of any of the
XX nucleotides into its complementary position. Accordingly, the nucleosides
XX and nucleotides are useful in developing functional nucleic acids
XX including antisense DNAs and RNAs, ribozymes and aptamers as reagents or
XX therapeutics in treating diseases by gene therapy. The produced nucleic
XX acids are chemically stable with improved ease of amplification.
XX replication and transcription for their preparation. This polynucleotide
XX sequence is a synthetic RNA 9A aptamer (100-mer) given in an
```


Best Local Similarity 100.0%; Pred. No. 8e-22; Mismatches 0; Indels 0; Gaps 0;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Matches 97; Conservative 0; Mismatches 1; Indels 2; Gaps 1;

QY 1 GGGAGUGGAGGAAUUAUCCGAGGCAUAGUGGACUCCGUCUUCUUAACACAGUUUAA 60
DB 1 GGGAGUGGAGGAAUUAUCCGAGGCAUAGUGGACUCCGUCUUCUUAACACAGUUUAA 60

QY 61 AUGGUUUUAGCAUAGCCUUAAGGACAGC 90
DB 61 AUGGUUUUAGCAUAGCCUUAAGGACAGC 90

RESULT 6
ADJ10053
ID ADJ10053 standard; RNA; 98 BP.
XX AC ADJ10053;
XX DT 17-JUN-2004 (first entry)
XX DE RNA aptamer (RNA9A) SeqID 1.
XX KW ss; unnatural base; 5'-substituted-2-oxo(1H)-pyridin-3-yl;
KW photoreactive group; biotin; fluorescent molecule;
KW 6-substituted-2-aminopurin-9-yl; aptamer; gene therapy.
XX OS Unidentified.
XX PN WO2004007713-A1.
XX PD 22-JAN-2004.
XX PF 28-FEB-2003; 2003WO-JP023342.
XX PR 17-JUL-2002; 2002JP-00208568.
XX PA (RIKE) RIKEN KK.
PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
PA (ADSC-) CENT ADVANCED SCI & TECHNOLOGY INCUBATIO.
XX PI Hirao I, Yokoyama S, Hirao M, Mitsui T;
XX WPI; 2004-122944/12.
XX Nucleosides or nucleotides comprising novel base particularly 5-
PT substituted-2-oxo(1H)-pyridin-3-yl group as base, useful in developing
PT functional nucleic acids as reagents or therapeutics in treating
PT diseases.
XX Example 4; SEQ ID NO 1; 78pp; Japanese.
XX This invention relates to nucleosides or nucleotides that a novel
CC unnatural base, namely the 5'-substituted-2-oxo(1H)-pyridin-3-yl group
CC as a base. Specifically, it refers to nucleic acid molecules integrated
CC with a base substituted at the 5-position with either a photoreactive
CC group (e.g. iodine or bromine), an alkenyl, alkynyl or amino group,
CC biotin or a derivative thereof or a fluorescent molecule selected from
CC fluorescein, 6-carboxyfluorescein, tetramethyl-7-carboxyrhodamine or
CC derivatives thereof. The present invention describes preparing nucleic
CC acids by carrying out transcription, replication or reverse transcription
CC with a nucleic acid containing a 6-substituted-2-aminopurin-9-yl group as
CC base which is applied as template for the integration of any of the
CC nucleosides into its complementary position. Accordingly, the nucleosides
CC and nucleotides are useful in developing functional nucleic acids
CC including antisense DNAs and RNAs, ribozymes and aptamers as reagents or
CC therapeutics in treating diseases by gene therapy. The produced nucleic
CC acids are chemically stable with improved ease of amplification,
CC replication and transcription for their preparation. This polynucleotide
CC sequence is an RNA aptamer (RNA9A) given in an exemplification of the
XX invention.
XX Sequence 98 BP; 24 A; 21 C; 24 G; 0 T; 29 U; 0 Other;

Query Match 84.4%; Score 84.4; DB 12; Length 98;
Best Local Similarity 97.0%; Pred. No. 7.9e-20; Mismatches 1; Indels 2; Gaps 1;
Matches 97; Conservative 0; Mismatches 1; Indels 2; Gaps 1;

QY 1 GGGAGUGGAGGAAUUAUCCGAGGCAUAGUGGACUCCGUCUUCUUAACACAGUUUAA 60
DB 1 GGGAGUGGAGGAAUUAUCCGAGGCAUAGUGGACUCCGUCUUCUUAACACAGUUUAA 58

QY 61 AUGGUUUUAGCAUAGCCUUAAGGACAGCAGCAAGCUUCGC 100
DB 59 AUGGUUUUAGCAUAGCCUUAAGGACAGCAGCAAGCUUCGC 98

RESULT 7
AAZ99051
ID AAZ99051 standard; RNA; 80 BP.
XX AC AAZ99051;
XX DT 21-JUN-2000 (first entry)
XX DE RNA aptamer #28 for binding Ras target protein.
XX KW Ras target protein; malignant tumour; signal transmission regulation;
KW cell proliferation; cell differentiation; aptamer; inflammation; ss.
XX OS Homo sapiens.
XX PN WO200009684-A1.
XX PD 24-FEB-2000.
XX PF 13-AUG-1999; 99WO-JP004399.
XX PR 14-AUG-1998; 98JP-00242596.
XX PR 24-NOV-1998; 98JP-00333284.
XX PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
XX PI Yokoyama S, Hirao I, Sakamoto K;
XX WPI; 2000-224330/19.
XX Nucleic acid e.g. RNA aptamer capable of binding specifically to Ras
PT target protein like Raf-1, useful in drug compositions to treat and
PT diagnose malignant tumors and inflammation.
XX Claim 6; Page 42; 59pp; Japanese.
XX The invention relates to novel nucleic acids which bind specifically to
CC the target protein of Ras, e.g. Raf-1. RNA aptamer (AAZ99051)
CC based on these sequences are useful in the treatment and diagnosis of
CC malignant tumors and inflammation. The nucleic acids can be used to
CC formulate medicinal compositions that are useful in the treatment of
CC malignant tumors and inflammation and for disease diagnosis by binding
CC specifically to Ras target protein and regulating transmission of signal
CC causing proliferation or differentiation of cells
XX Sequence 80 BP; 20 A; 16 C; 19 G; 0 T; 25 U; 0 Other;

Query Match 80.0%; Score 80; DB 3; Length 80;
Best Local Similarity 100.0%; Pred. No. 2.7e-18; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGAGUGGAGGAAUUAUCCGAGGCAUAGUGGACUCCGUCUUCUUAACACAGUUUAA 60
DB 1 GGGAGUGGAGGAAUUAUCCGAGGCAUAGUGGACUCCGUCUUCUUAACACAGUUUAA 60

QY 61 AUGGUUUUAGCAUAGCCU 80
DB 61 AUGGUUUUAGCAUAGCCU 80

```
RESULT 8
ADJ10066
ID ADJ10066 standard; DNA; 147 BP.
XX
AC ADJ10066;
XX
DT 17-JUN-2004 (first entry)
XX
DE Synthetic RNA OC aptamer (100-mer).
XX
SS; unnatural base; 5'-substituted-2-oxo(1H)-pyridin-3-yl;
KW photoreactive group; biotin; fluorescent molecule;
KW 6-substituted-2-aminopurin-9-yl; aptamer; gene therapy.
XX
OS Synthetic.
XX
PN WO2004007713-A1.
XX
PD 22-JAN-2004.
XX
PF 28-FEB-2003; 2003WO-JF002342.
XX
PR 17-JUL-2002; 2002JP-00208568.
XX
PA (RIKE ) RIKEN KK.
XX
PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
XX
PA (ADSC-) CENT ADVANCED SCI & TECHNOLOGY INCUBATIO.
XX
PI Hiraio I, Yokoyama S, Hirao M, Mitsui T;
XX
WPI; 2004-122944/12.
XX
DR Nucleosides or nucleotides comprising novel base particularly 5-
PT substituted-2-oxo(1H)-pyridin-3-yl group as base, useful in developing
PT functional nucleic acids as reagents or therapeutics in treating
PT diseases.
XX
PS Disclosure; Fig 10; 78pp; Japanese.
XX
CC This invention relates to nucleosides or nucleotides that a novel
CC unnatural base, namely the 5'-substituted-2-oxo(1H)-pyridin-3-yl group
CC as a base. Specifically, it refers to nucleic acid molecules integrated
CC with a base substituted at the 5-position with either a photoreactive
CC group (e.g. iodine or bromine), an alkenyl, alkynyl or amino group,
CC biotin or a derivative thereof or a fluorescent molecule selected from
CC fluorescein, 6-carboxyfluorescein, tetramethyl-7-carboxyrhodamine or
CC derivatives thereof. The present invention describes preparing nucleic
CC acids by carrying out transcription, replication or reverse transcription
CC with a nucleic acid containing a 6-substituted-2-aminopurin-9-yl group as
CC base which is applied as template for the integration of any of the
CC nucleotides into its complementary position. Accordingly, the nucleosides
CC and nucleotides are useful in developing functional nucleic acids
CC including antisense DNAs and RNAs, ribozymes and aptamers as reagents or
CC therapeutics in treating diseases by gene therapy. The produced nucleic
CC acids are chemically stable with improved ease of amplification,
CC replication and transcription for their preparation. This polynucleotide
CC sequence is a synthetic RNA OC aptamer (100-mer) given in an
CC exemplification of the invention.
XX
SQ Sequence 147 BP; 32 A; 34 C; 37 G; 0 T; 44 U; 0 Other;

Query Match 50.6%; Score 50.6; DB 12; Length 147;
Best Local Similarity 75.2%; Pred. No. 8e-08;
Matches 76; Conservative 0; Mismatches 24; Indels 1; Gaps 1;

QY 1 GGGAGUGGAGGAUAUUAUUGGAGCAUUGGAGCUCGUCUUAACACAGU-UGUA 59
DB 1 GGGAGUGGAGGAUAUUAUUGGAGCAUUGGAGCUCGUCUUAACACAGU-UGUA 60

QY 60 AAUUGUUUUAUGCAUUGCCTUAGCGACAGCAAGCUUUGC 100
DB 61 CACCUGAACAGCAUUGCCTUAGCGACAGCAAGCUUUGC 101

RESULT 9
AAZ99076
ID AAZ99076 standard; RNA; 45 BP.
XX
AC AAZ99076;
XX
DT 21-JUN-2000 (first entry)
XX
DE Ras target protein-RNA binding sequence #1 for generating primers.
XX
SS; Ras target protein; malignant tumour; signal transduction regulation;
KW Ras target protein; malignant tumour; signal transduction regulation;
KW cell proliferation; cell differentiation; aptamer; inflammation; ss.
XX
OS Homo sapiens.
XX
PN WO200009684-A1.
XX
PD 24-FEB-2000.
XX
PF 13-AUG-1999; 99WO-JP004399.
XX
PR 14-AUG-1998; 98JP-00242596.
XX
PR 24-NOV-1998; 98JP-00333284.
XX
PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
XX
PI Yokoyama S, Hirao I, Sakamoto K;
XX
WPI; 2000-224330/19.
XX
DR Nucleic acid e.g. RNA aptamer capable of binding specifically to Ras
PT target protein like Raf-1, useful in drug compositions to treat and
PT diagnose malignant tumors and inflammation.
XX
PS Disclosure; Page 52; 59pp; Japanese.
XX
CC The invention relates to novel nucleic acids which bind specifically to
CC the target protein of Ras, e.g. Raf-1. RNA sequences (AAZ99076-299077)
CC represent the sequence of aptamer inserts that bind the Ras target
CC protein which are used to generate PCR primers. Aptamers based on these
CC sequences are useful in the treatment and diagnosis of malignant tumours
CC and inflammation. The nucleic acids can be used to formulate medicinal
CC compositions that are useful in the treatment of malignant tumours and
CC inflammation and for disease diagnosis by binding specifically to Ras
CC target protein and regulating transmission of signal causing
CC proliferation or differentiation of cells
XX
SQ Sequence 45 BP; 11 A; 10 C; 7 G; 0 T; 17 U; 0 Other;

Query Match 45.0%; Score 45; DB 3; Length 45;
Best Local Similarity 100.0%; Pred. No. 5.3e-06;
Matches 45; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 27 AUGUGGACUCGUCUUCUUAACACAGUUAUUAUUGGUUUUAG 71
DB 1 AUGUGGACUCGUCUUCUUAACACAGUUAUUAUUGGUUUUAG 45

RESULT 10
AAC75113/C
ID AAC75113 standard; cDNA; 748 BP.
XX
AC AAC75113;
XX
DT 08-FEB-2001 (first entry)
XX
DE Human ORFX ORF668 polynucleotide sequence SEQ ID NO:1335.
XX
KW Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;
KW vulnary; antipapillary; antipapillary; antipapillary; antipapillary;
KW anticonvulsant; osteopathic; antithrombotic; immunosuppressant; cardiac;
KW immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
```

hypotensive; dermatological; immunosuppressive; antiinflammatory;
 KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
 KW antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
 KW neurodegenerative disorder; osteoarthritis; graft vs host disease;
 KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
 KW cholesterol ester storage; systemic lupus erythematosus; infection;
 KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
 KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
 KW bone damage; cartilage damage; antiinflammatory disease; coagulation;
 KW thrombosis; contraceptive; ss.

XX Homo sapiens.

OS WO200058473-A2.

PN 05-OCT-2000.

PD 31-MAR-2000; 2000WO-US008621.

PF 31-MAR-1999; 99US-0127607P.

PR 02-APR-1999; 99US-0127636P.

PR 05-APR-1999; 99US-0127728P.

PR 30-MAR-2000; 2000US-00540763.

XX (CURA-) CURAGEN CORP.

XX Shimkets RA, Leach M;

XX WPI; 2000-602362/57.

DR P-PSDB; AAB40904.

XX Novel nucleic acids and peptides derived from open reading frame X,

PT useful for treating e.g. cancers, proliferative disorders,

PT neurodegenerative disorders and cardiovascular disease.

XX Claim 5; Page 1146-1147; 5507pp; English.

PS AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,

CC which represent the human ORFX open reading frames 1 to 3161. The ORFX

CC sequences have activities such as: cytostatic; hepatotropic; vulnery;

CC antipsoriatic; antiparkinsonian; nontropic; neuroprotective; osteopathic;

CC anticonvulsant; antiarthritic; immunosuppressant; immunostimulant;

CC cardiant; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive;

CC dermatological; immunosuppressive; antiinflammatory; antibacterial;

CC antiviral; antifungal; antirheumatic; antithyroid; and antianaemic. The

CC sequences can be used for determining the presence of or predisposition

CC to, or preventing or treating pathological conditions associated with an

CC ORFX-associated disorder. The nucleic acids can be used to express ORFX

CC proteins in gene therapy vectors. The proteins and nucleic acids may be

CC used to treat cancers, proliferative disorders, neurodegenerative

CC disorders, osteoarthritis, graft vs host disease, cardiovascular disease,

CC diabetes mellitus, hypertension, hypothyroidism, cholesterol ester

CC storage, systemic lupus erythematosus, severe combined immunodeficiency

CC (SCID), AIDS viral, bacterial or fungal infection, malaria, autoimmune

CC disorders, asthma, allergies, aplastic anaemia, burns, wounds, bone and

CC cartilage damage, nocturnal haemoglobinuria, antiinflammatory disease; to

RESULT 11

ABN24508/c

ID ABN24508 standard; cDNA; 748 BP.

XX AC ABN24508;

XX DT 24-JUN-2002 (first entry)

XX DE Human ORFX polynucleotide sequence SEQ ID NO:17493.

XX KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;

XX KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;

XX KW degenerative disorder; osteoarthritis; neurodegenerative disorder;

XX KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;

XX KW hypertension; hypothyroidism; cholesterol ester storage disease;

XX KW immune deficiency; immune disorder; infectious disease;

XX KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;

XX KW myasthenia gravis; gene; ss.

XX OS Homo sapiens.

XX WO2000192523-A2.

XX 06-DEC-2001.

XX 29-MAY-2001; 2001WO-US010836.

XX 30-MAY-2000; 2000US-0206132P.

XX 29-AUG-2000; 2000US-0228716P.

XX (CURA-) CURAGEN CORP.

XX Shimkets RA, Leach MD;

XX WPI; 2002-106308/14.

XX P-PSDB; ABP08756.

XX Novel human polypeptides and polynucleotides useful for diagnosing,

PT preventing and treating cardiovascular disease, neurodegenerative,

PT hyperproliferative disorders and autoimmune disorders.

PS Disclosure; SEQ ID NO 17493; 1037pp; English.

XX The present invention describes substantially purified human proteins

CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1

CC in the specification). ABN15762 to ABN27252 encode the human ORFX

CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for

CC treating or preventing a pathology associated with an ORFX-associated

CC disorder in humans, and in the manufacture of a medicament for treating a

CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide

CC sequences can be used in gene therapy. ORFX sequences can be used in the

CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,

CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,

CC osteoarthritis, neurodegenerative disorders, disorders related to organ

CC transplantation, cardiovascular diseases, diabetes mellitus, systemic

hypotensive; dermatological; immunosuppressive; antiinflammatory;
 KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
 KW antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
 KW neurodegenerative disorder; osteoarthritis; graft vs host disease;
 KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
 KW cholesterol ester storage; systemic lupus erythematosus; infection;
 KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
 KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
 KW bone damage; cartilage damage; antiinflammatory disease; coagulation;
 KW thrombosis; contraceptive; ss.

XX Homo sapiens.

OS WO200058473-A2.

PN 05-OCT-2000.

PD 31-MAR-2000; 2000WO-US008621.

PF 31-MAR-1999; 99US-0127607P.

PR 02-APR-1999; 99US-0127636P.

PR 05-APR-1999; 99US-0127728P.

PR 30-MAR-2000; 2000US-00540763.

XX (CURA-) CURAGEN CORP.

XX Shimkets RA, Leach M;

XX WPI; 2000-602362/57.

DR P-PSDB; AAB40904.

XX Novel nucleic acids and peptides derived from open reading frame X,

PT useful for treating e.g. cancers, proliferative disorders,

PT neurodegenerative disorders and cardiovascular disease.

XX Claim 5; Page 1146-1147; 5507pp; English.

PS AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,

CC which represent the human ORFX open reading frames 1 to 3161. The ORFX

CC sequences have activities such as: cytostatic; hepatotropic; vulnery;

CC antipsoriatic; antiparkinsonian; nontropic; neuroprotective; osteopathic;

CC anticonvulsant; antiarthritic; immunosuppressant; immunostimulant;

CC cardiant; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive;

CC dermatological; immunosuppressive; antiinflammatory; antibacterial;

CC antiviral; antifungal; antirheumatic; antithyroid; and antianaemic. The

CC sequences can be used for determining the presence of or predisposition

CC to, or preventing or treating pathological conditions associated with an

CC ORFX-associated disorder. The nucleic acids can be used to express ORFX

CC proteins in gene therapy vectors. The proteins and nucleic acids may be

CC used to treat cancers, proliferative disorders, neurodegenerative

CC disorders, osteoarthritis, graft vs host disease, cardiovascular disease,

CC diabetes mellitus, hypertension, hypothyroidism, cholesterol ester

CC storage, systemic lupus erythematosus, severe combined immunodeficiency

CC (SCID), AIDS viral, bacterial or fungal infection, malaria, autoimmune

CC disorders, asthma, allergies, aplastic anaemia, burns, wounds, bone and

CC cartilage damage, nocturnal haemoglobinuria, antiinflammatory disease; to

hypotensive; dermatological; immunosuppressive; antiinflammatory;
 KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
 KW antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
 KW neurodegenerative disorder; osteoarthritis; graft vs host disease;
 KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
 KW cholesterol ester storage; systemic lupus erythematosus; infection;
 KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
 KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
 KW bone damage; cartilage damage; antiinflammatory disease; coagulation;
 KW thrombosis; contraceptive; ss.

XX Homo sapiens.

OS WO200058473-A2.

PN 05-OCT-2000.

PD 31-MAR-2000; 2000WO-US008621.

PF 31-MAR-1999; 99US-0127607P.

PR 02-APR-1999; 99US-0127636P.

PR 05-APR-1999; 99US-0127728P.

PR 30-MAR-2000; 2000US-00540763.

XX (CURA-) CURAGEN CORP.

XX Shimkets RA, Leach M;

XX WPI; 2000-602362/57.

DR P-PSDB; AAB40904.

XX Novel nucleic acids and peptides derived from open reading frame X,

PT useful for treating e.g. cancers, proliferative disorders,

PT neurodegenerative disorders and cardiovascular disease.

XX Claim 5; Page 1146-1147; 5507pp; English.

PS AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,

CC which represent the human ORFX open reading frames 1 to 3161. The ORFX

CC sequences have activities such as: cytostatic; hepatotropic; vulnery;

CC antipsoriatic; antiparkinsonian; nontropic; neuroprotective; osteopathic;

CC anticonvulsant; antiarthritic; immunosuppressant; immunostimulant;

CC cardiant; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive;

CC dermatological; immunosuppressive; antiinflammatory; antibacterial;

CC antiviral; antifungal; antirheumatic; antithyroid; and antianaemic. The

CC sequences can be used for determining the presence of or predisposition

CC to, or preventing or treating pathological conditions associated with an

CC ORFX-associated disorder. The nucleic acids can be used to express ORFX

CC proteins in gene therapy vectors. The proteins and nucleic acids may be

CC used to treat cancers, proliferative disorders, neurodegenerative

CC disorders, osteoarthritis, graft vs host disease, cardiovascular disease,

CC diabetes mellitus, hypertension, hypothyroidism, cholesterol ester

CC storage, systemic lupus erythematosus, severe combined immunodeficiency

CC (SCID), AIDS viral, bacterial or fungal infection, malaria, autoimmune

CC disorders, asthma, allergies, aplastic anaemia, burns, wounds, bone and

CC cartilage damage, nocturnal haemoglobinuria, antiinflammatory disease; to

hypotensive; dermatological; immunosuppressive; antiinflammatory;
 KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
 KW antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
 KW neurodegenerative disorder; osteoarthritis; graft vs host disease;
 KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
 KW cholesterol ester storage; systemic lupus erythematosus; infection;
 KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
 KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
 KW bone damage; cartilage damage; antiinflammatory disease; coagulation;
 KW thrombosis; contraceptive; ss.

XX Homo sapiens.

OS WO200058473-A2.

PN 05-OCT-2000.

PD 31-MAR-2000; 2000WO-US008621.

PF 31-MAR-1999; 99US-0127607P.

PR 02-APR-1999; 99US-0127636P.

PR 05-APR-1999; 99US-0127728P.

PR 30-MAR-2000; 2000US-00540763.

XX (CURA-) CURAGEN CORP.

XX Shimkets RA, Leach M;

XX WPI; 2000-602362/57.

DR P-PSDB; AAB40904.

XX Novel nucleic acids and peptides derived from open reading frame X,

PT useful for treating e.g. cancers, proliferative disorders,

PT neurodegenerative disorders and cardiovascular disease.

XX Claim 5; Page 1146-1147; 5507pp; English.

PS AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,

CC which represent the human ORFX open reading frames 1 to 3161. The ORFX

CC sequences have activities such as: cytostatic; hepatotropic; vulnery;

CC antipsoriatic; antiparkinsonian; nontropic; neuroprotective; osteopathic;

CC anticonvulsant; antiarthritic; immunosuppressant; immunostimulant;

CC cardiant; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive;

CC dermatological; immunosuppressive; antiinflammatory; antibacterial;

CC antiviral; antifungal; antirheumatic; antithyroid; and antianaemic. The

CC sequences can be used for determining the presence of or predisposition

CC to, or preventing or treating pathological conditions associated with an

CC ORFX-associated disorder. The nucleic acids can be used to express ORFX

CC proteins in gene therapy vectors. The proteins and nucleic acids may be

CC used to treat cancers, proliferative disorders, neurodegenerative

CC disorders, osteoarthritis, graft vs host disease, cardiovascular disease,

CC diabetes mellitus, hypertension, hypothyroidism, cholesterol ester

CC storage, systemic lupus erythematosus, severe combined immunodeficiency

CC (SCID), AIDS viral, bacterial or fungal infection, malaria, autoimmune

CC disorders, asthma, allergies, aplastic anaemia, burns, wounds, bone and

CC cartilage damage, nocturnal haemoglobinuria, antiinflammatory disease; to

hypotensive; dermatological; immunosuppressive; antiinflammatory;
 KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
 KW antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
 KW neurodegenerative disorder; osteoarthritis; graft vs host disease;
 KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
 KW cholesterol ester storage; systemic lupus erythematosus; infection;
 KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
 KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
 KW bone damage; cartilage damage; antiinflammatory disease; coagulation;
 KW thrombosis; contraceptive; ss.

XX Homo sapiens.

OS WO200058473-A2.

PN 05-OCT-2000.

PD 31-MAR-2000; 2000WO-US008621.

PF 31-MAR-1999; 99US-0127607P.

PR 02-APR-1999; 99US-0127636P.

PR 05-APR-1999; 99US-0127728P.

PR 30-MAR-2000; 2000US-00540763.

XX (CURA-) CURAGEN CORP.

XX Shimkets RA, Leach M;

XX WPI; 2000-602362/57.

DR P-PSDB; AAB40904.

XX Novel nucleic acids and peptides derived from open reading frame X,

PT useful for treating e.g. cancers, proliferative disorders,

PT neurodegenerative disorders and cardiovascular disease.

XX Claim 5; Page 1146-1147; 5507pp; English.

PS AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,

CC which represent the human ORFX open reading frames 1 to 3161. The ORFX

CC sequences have activities such as: cytostatic; hepatotropic; vulnery;

CC antipsoriatic; antiparkinsonian; nontropic; neuroprotective; osteopathic;

CC anticonvulsant; antiarthritic; immunosuppressant; immunostimulant;

CC cardiant; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive;

CC dermatological; immunosuppressive; antiinflammatory; antibacterial;

CC antiviral; antifungal; antirheumatic; antithyroid; and antianaemic. The

CC sequences can be used for determining the presence of or predisposition

QY 18 UCGAGGCAUUGUGGACUCCGCUUCCUCAAACCGAUUAUAAUUGUUUAGCAUUG 77
 Db 317 TTGGGTGCGACCTCGACCGCGGCTTCTTCAGACCGTTGATGAACGGTTGTAGGTCTG 258
 QY 78 CCUUAGCGACGACGACG 94
 Db 257 CCCTGGCGACGGGAAGC 241

RESULT 12
 AAS59583
 ID AAS59583 standard; DNA; 15776 BP.
 AC AAS59583;
 XX
 DT 13-FEB-2002 (first entry)
 XX
 DE Propionibacterium acnes immunogenic protein encoding DNA #78.
 XX
 KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
 KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
 KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
 KW dermatological; osteopathic; neuroprotectant; ds.
 XX
 OS Propionibacterium acnes.
 XX
 PN WO200181581-A2.
 XX
 PD 01-NOV-2001.
 XX
 PF 20-APR-2001; 2001WO-US012865.
 XX
 PR 21-APR-2000; 2000US-0199047P.
 PR 02-JUN-2000; 2000US-0208841P.
 PR 07-JUL-2000; 2000US-0216747P.
 XX
 PA (CORI-) CORIXA CORP.

XX Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
 PI L'Maisonneuve J, Zhang Y, Jen S, Carter D;
 XX
 DR WPI; 2001-616774/71.
 XX
 XX Propionibacterium acnes polypeptides and nucleic acids useful for
 PT vaccinating against and diagnosing infections, especially useful for
 PT treating acne vulgaris.
 XX
 PS Claim 1; SEQ ID NO 78; 1069pp; English.
 XX

XX Sequences AAS59506-AAS59804 represent DNA molecules encoding
 CC Propionibacterium acnes immunogenic polypeptides. The proteins and their
 CC associated DNA sequences are used in the treatment, prevention and
 CC diagnosis of medical conditions caused by P. acnes. The disorders include
 CC SAPHO syndrome (synovitis, acne, pustulosis, hypertosis and
 CC osteomyelitis), uveitis and endophthalmitis. P. acnes is also involved in
 CC infections of bone, joints and the central nervous system, however it is
 CC particularly involved in the inflammatory lesions associated with acne
 CC vulgaris. A method for detecting the presence or absence of P. acnes in a
 CC patient comprises contacting a sample with a binding agent that binds to
 CC the proteins of the invention and determining the amount of bound protein
 CC in the sample. The polypeptides may be used as antigens in the production
 CC of antibodies specific for P. acnes proteins. These antibodies can be
 CC used to downregulate expression and activity of P. acnes polypeptides and
 CC therefore treat P. acnes infections. The antibodies may also be used as
 CC diagnostic agents for determining P. acnes presence, for example, by
 CC enzyme linked immunosorbent assay (ELISA). This sequence encodes the
 CC polypeptides shown in AAU57347-AAU57508 and AAU67590-AAU67591. Note: The
 CC sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at http://wipo.int/pub/published_pct_sequences

XX Sequence 15776 BP; 3393 A; 4931 C; 4483 G; 2969 T; 0 U; 0 Other;

Query Match 30.6%; Score 30.6; DB 4; Length 15776;
 Best Local Similarity 46.8%; Pred. No. 4;
 Matches 36; Conservative 12; Mismatches 29; Indels 0; Gaps 0;
 QY 18 UCGAGGCAUUGUGGACUCCGCUUCCUCAAACCGAUUAUAAUUGUUUAGCAUUG 77
 Db 8427 TTGGGTGCGACCTCGACCGCGGCTTCTTCAGACCGTTGATGAACGGTTGTAGGTCTG 8486
 QY 78 CCUUAGCGACGACGACG 94
 Db 8487 CCCTGGCGACGGGAAGC 8503

RESULT 13
 ACF64512
 ID ACF64512 standard; DNA; 15776 BP.

XX AC ACF64512;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Propionibacterium acnes DNA contig sequence #78.

XX KW Acne vulgaris; antiseborrheic; dermatological; antibacterial;
 KW immunostimulant; immune response; vaccine; ds.
 XX
 OS Propionibacterium acnes.

XX WO2003033515-A1.
 XX
 PD 24-APR-2003.

XX PF 11-OCT-2002; 2002WO-US032727.
 XX
 PR 15-OCT-2001; 2001US-00978825.

XX
 PA (CORI-) CORIXA CORP.
 XX

XX Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;
 PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
 PI Barth B, Vallieve-Douglas J;
 XX
 DR WPI; 2003-381789/36.

XX New Propionibacterium acnes polypeptides and polynucleotides encoding the
 PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
 PT or for stimulating an immune response specific for a P. acnes protein.

XX Claim 1; SEQ ID NO 78; 1481pp; English.

XX The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
 CC encoding a Propionibacterium acnes protein. The invention also relates to
 CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
 CC immunogenic fragments of P. acnes polypeptides. The invention
 CC additionally encompasses expression vectors and host cells comprising a
 CC polynucleotide of the invention; antibodies against polypeptides of the
 CC invention; fusion proteins comprising a polypeptide of the invention; a
 CC method for stimulating an immune response specific for a P. acnes
 CC polypeptide and an isolated T cell population comprising T cells prepared
 CC via this method; a vaccine composition (comprising P. acnes polypeptides,
 CC polynucleotides, antibodies, fusion proteins, T cell populations, or
 CC antigen-presenting cells that express the polypeptide); a method and kit
 CC for detecting or determining the presence or absence of P. acnes in a
 CC patient; and a method for inhibiting the development of P. acnes in a
 CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
 CC proteins, T cell populations or antigen-presenting cells that express the
 CC polypeptides are useful for diagnosing, preventing or treating acne
 CC vulgaris, or for stimulating an immune response specific for a P. acnes
 CC protein. The polynucleotides can also be used as probes or primers for
 CC nucleic acid hybridisation. The vaccine composition is useful for the
 CC stimulation of an immune response against P. acnes, or for treating acne,
 CC and the kit is useful for performing a diagnostic assay. The present

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 30, 2004, 11:12:16 ; Search time 51.1111 Seconds
(without alignments)
1390.674 Million cell updates/sec

Title: US-09-529-397C-25

perfect score: 100

Sequence: 1 gggaguggaggaaucg.....uaggacagcaagcucucg 100

Scoring table: IDENTITY_NUC

Searched: 824507 secs, 355394441 residues

Total number of hits satisfying chosen parameters: 1649014

Minimum DB seq length: 0

Maximum DB sec length: 200000000

post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents NA:*

```
1: /can2 6/ptodata/1/ina/5A COMB.seq:*
```

2: /cqn2_6/ptodata/1/ina/5B_COMB.seq:*

3: /cgn2-6/ptodata/1/ina/6A COMB.seq: *

4: /cgn2_6/ptodata/1/ina/6B_COMB.seq:*

5: /cgn2_6/ptodata/1/ina/PCTUS_COMB.se

6: /cgn2_6/ptodata/1/ina/backfiles1.se

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query			DB	ID	Description	
	Score	Match	Length				
C	1	30.4	30.4	366	4	US-09-328-353-608	
	2	29.8	29.8	4285	3	Sequence 608, Appl	
	3	27.4	27.4	405	4	Sequence 1, Appli	
	4	27.4	27.4	405	4	Sequence 6441, Ap	
	5	27.4	27.4	405	4	Sequence 21723, A	
	6	27	27.0	208	4	Sequence 3, Appli	
	C	7	26.8	26.8	415	4	Sequence 21500, A
		8	25.8	25.8	798	4	Sequence 26061, A
9		25.8	25.8	798	4	Sequence 162, Appl	
10		25.6	25.6	372	4	Sequence 162, Appl	
11		25.6	25.6	372	4	Sequence 798, Appl	
12		25.2	25.2	355	4	Sequence 798, Appl	
C		13	25.2	25.2	786431	4	Sequence 8830, Ap
		14	25	25.0	246	4	Sequence 3, Appli
	15	25	25.0	960	4	Sequence 35958, A	
	16	25	25.0	1830121	4	Sequence 1916, Ap	
	17	25	25.0	1830121	4	Sequence 1, Appl	
	18	25	25.0	1830121	4	Sequence 1, Appl	
	19	24.8	24.8	2775	3	Sequence 1, Appl	
	20	24.8	24.8	3786	3	Sequence 4695, Ap	
21	24.8	24.8	3786	3	Sequence 42, Appl		
22	24.8	24.8	3786	3	Sequence 42, Appl		
23	24.8	24.8	3786	4	Sequence 42, Appl		
24	24.8	24.8	3786	4	Sequence 42, Appl		
25	24.8	24.8	7399	2	Sequence 9, Appli		
26	24.8	24.8	9709	3	Sequence 5, Appli		
27	24.8	24.8	9709	3	Sequence 1, Appli		

```
; TYPE: DNA
; ORGANISM: Populus balsamifera subsp. trichocarpa
US-09-410-464-1

Query Match      29.8%; Score 29.8; DB 3; Length 4285;
Best Local Similarity 33.3%; Pred. No. 0.33;
Matches 27; Conservative 22; Mismatches 32; Indels 0; Gaps 0;

QY 8 GAGAAUUCAGGAGCAUAGUGGAGCUCGUCUCCUUAACCAAGUUAUAAUUGGU 67
Db 1193 GATTATCTGTAACCTTCTTGGTTTATATGCTTCAATCCATATTATTGTTT 1252

QY 68 UAGCAUAGCCUUAAGGCA 88
Db 1253 TTATGATTTCTTAGATACA 1273

RESULT 3
US-09-270-767-6441
; Sequence 6441, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 6441
; LENGTH: 405
; TYPE: DNA
; ORGANISM: Drosophila melanogaster
US-09-270-767-6441

Query Match      27.4%; Score 27.4; DB 4; Length 405;
Best Local Similarity 35.5%; Pred. No. 1.2;
Matches 33; Conservative 19; Mismatches 41; Indels 0; Gaps 0;

QY 7 GGAGAAUUCAGGAGCAUAGUGGAGCUCGUCUCCUUAACCAAGUUAUAAUUGGU 66
Db 227 GGTGTAATCCATTGGTTCAATTTGGTCTCTCAACTCAAACTGTAATAATCCAT 286

QY 67 UUAGCAUAGCCUUAAGGCAAGCAAGCUUG 99
Db 287 TTTTAAAGTCGCTGAACCAACCGAAGATCTG 319

RESULT 4
US-09-270-767-21723
; Sequence 21723, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 21723
; LENGTH: 405
; TYPE: DNA
; ORGANISM: Drosophila melanogaster
US-09-270-767-21723

Query Match      27.4%; Score 27.4; DB 4; Length 405;
Best Local Similarity 35.5%; Pred. No. 1.2;
Matches 33; Conservative 19; Mismatches 41; Indels 0; Gaps 0;

QY 7 GGAGAAUUCAGGAGCAUAGUGGAGCUCGUCUCCUUAACCAAGUUAUAAUUGGU 66
Db 227 GGTGTAATCCATTGGTTCAATTTGGTCTCTCAACTCAAACTGTAATAATCCAT 286

QY 67 UUAGCAUAGCCUUAAGGCAAGCAAGCUUG 99
Db 287 TTTTAAAGTCGCTGAACCAACCGAAGATCTG 319

RESULT 5
US-08-675-773B-3/c
; Sequence 3, Application US/08675773B
; Patent No. 6166288
; GENERAL INFORMATION:
; APPLICANT: DIAMOND, LISA E
; APPLICANT: LOGAN, JOHN S
; APPLICANT: BYRNE, GUERARD W
; APPLICANT: SHARMA, AJAY
; TITLE OF INVENTION: METHOD OF PRODUCING TRANSGENIC ANIMALS
; TITLE OF INVENTION: FOR XENOTRANSPLANTATION. . .
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK, P.L.L.C.
; STREET: 419 SEVENTH STREET, N.W., SUITE 300
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/08/675,773B
; FILING DATE: 03-JUL-1996
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: COOPER, IVER P.
; REGISTRATION NUMBER: 28,005
; REFERENCE/DOCKET NUMBER: DIAMOND-1A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3791 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-675-773B-3

Query Match      27.4%; Score 27.4; DB 3; Length 3791;
Best Local Similarity 41.6%; Pred. No. 2.5;
Matches 32; Conservative 14; Mismatches 31; Indels 0; Gaps 0;

QY 19 CGAGGCAUAGUGGAGCUCGUCUCCUUAACCAAGUUAUAAUUGGUUUAAGCAUUGC 78
Db 624 CCAGGATTCAGACAGCCCTGTCTCCCTCAACCCCTCTATTAGATGTTGTGAGCATTTTC 565

QY 79 CUUAGCGCAGCAGCAAGCU 95
Db 564 CATGGGACTTGATGCT 548

RESULT 6
US-09-513-999C-21500/c
; Sequence 21500, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6783961
```



```

RESULT 8
US-08-956-171E-162
; Sequence 162, Application US/08956171E
; Patent No. 6593114
; GENERAL INFORMATION:
; APPLICANT: Charles Kunsch
; Gil H. Choi
; Patrick S. Dillon
; Craig A. Rosen
; Steven C. Barash
; Michael R. Fannon
; TITLE OF INVENTION: Staphylococcus aureus Polynucleotides and Sequences
; NUMBER OF SEQUENCES: 5256
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Human Genome Sciences, Inc.
; STREET: 9410 Key West Avenue
; CITY: Rockville
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20850
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage
; COMPUTER: HP Vectra 486/33
; OPERATING SYSTEM: MSDOS version 6.2
; SOFTWARE: ASCII Text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/956,171E
; FILING DATE: 20-Oct-1997
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/009,861
; FILING DATE: January 5, 1996
; APPLICATION NUMBER: 08/781,966
; FILING DATE: January 3, 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Mark J. Hyman
; REGISTRATION NUMBER: 46,789
; REFERENCE/DOCKET NUMBER: PB248P1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (240) 314-1224
; TELEFAX: (301) 309-8439
; INFORMATION FOR SEQ ID NO: 162:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 798 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 162:
US-08-956-171E-162

Query Match 25.8%; Score 25.8; DB 4; Length 798;
Best Local Similarity 31.2%; Pred. No. 5.7;
Matches 24; Conservative 21; Mismatches 32; Indels 0; Gaps 0;

Qy 22 GGCAUAGUGGACUCCGUCUCCUCAAACCGAUUAUAAUUGGUUUGAUGCCUU 81
Db 196 GGCACTTTTCACTTCTTCTTTCTTTTTCGTCAGTATTAAAGTGGTTTAGATTCCTCAT 255

```

Db 256 CGTTCTGCGATTCT 272

RESULT 9
US-08-781-986A-162
; Sequence 162, Application US/08781986A
; Patent No. 6737248
; GENERAL INFORMATION:
; APPLICANT: Charles Kunsch
; TITLE OF INVENTION: Staphylococcus aureus Polynucleotides and Sequences
; NUMBER OF SEQUENCES: 5255
; CORRESPONDENCE ADDRESS:
;


```
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
US-08-781-986A-798

Query Match      25.6%; Score 25.6; DB 4; Length 372;
Best Local Similarity 36.9%; Pred. No. 5.3; 25; Indels 0; Gaps 0;
Matches 24; Conservative 16; Mismatches 23;

QY 27 AUGUGACUCCGUCUCCUUAACACAGUUAUAAUUGGUUAGCAUAGCCUUAAGCGA 86
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 223 ATTCAACACCTTTTCTTTTCATACCTTTTAAACAGGTTGTGTCATTGNTTTTGA 282
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 87 CAGCA 91
Db 283 GGCCA 287

RESULT 12
US-09-513-999C-8830
; Sequence 8830, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; FILE REFERENCE: 59.US2.REG
; CURRENT APPLICATION NUMBER: US/09/513,999C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 36681
; SOFTWARE: Patent.pm
; SEQ ID NO 8830
; LENGTH: 355
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 309
; OTHER INFORMATION: k=g or t
; NAME/KEY: misc_feature
; LOCATION: 319
; OTHER INFORMATION: r=a or g
US-09-513-999C-8830

Query Match      25.2%; Score 25.2; DB 4; Length 355;
Best Local Similarity 37.1%; Pred. No. 7.3; 23; Indels 0; Gaps 0;
Matches 23; Conservative 16; Mismatches 23;

QY 27 AUGUGACUCCGUCUCCUUAACACAGUUAUAAUUGGUUAGCAUAGCCUUAAGCGA 86
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 166 ATTCAATTCCTGTTTCTTAAACCGTTTTTCTTTGTTGTTGTCATTAGCATGTGGA 225
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 87 CA 88
Db 226 CA 227

RESULT 13
US-09-751-389-3/c
; Sequence 3, Application US/09751389
; Patent No. 663034
; GENERAL INFORMATION:
; APPLICANT: GUEGLER, Karl et al
; TITLE OF INVENTION: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC
```

```
; TITLE OF INVENTION: ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: CL001067
; CURRENT APPLICATION NUMBER: US/09/751.389
; CURRENT FILING DATE: 2001-01-02
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 786431
; TYPE: DNA
; ORGANISM: Human
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(786431)
; OTHER INFORMATION: n = A,T,C or G
US-09-751-389-3

Query Match      25.2%; Score 25.2; DB 4; Length 786431;
Best Local Similarity 42.6%; Pred. No. 91;
Matches 23; Conservative 13; Mismatches 18; Indels 0; Gaps 0;

QY 44 CUUCAACCGUUAUAAUUGGUUUAAGCAUAGCCUUAAGCGACAGCAAGCUUC 97
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 507097 CTCGAGAGCTGTGATATATTGTTTAAAGCCATTGACTTAGTGACATTTGTTTC 507044
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 14
US-09-513-999C-35958
; Sequence 35958, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; FILE REFERENCE: 59.US2.REG
; CURRENT APPLICATION NUMBER: US/09/513,999C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 36681
; SOFTWARE: Patent.pm
; SEQ ID NO 35958
; LENGTH: 246
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 137
; OTHER INFORMATION: m=a or c
; NAME/KEY: misc_feature
; LOCATION: 143
; OTHER INFORMATION: r=a or g
; NAME/KEY: misc_feature
; LOCATION: 153
; OTHER INFORMATION: w=a or t
; NAME/KEY: misc_feature
; LOCATION: 170
; OTHER INFORMATION: b=c or g or t
US-09-513-999C-35958

Query Match      25.0%; Score 25; DB 4; Length 246;
Best Local Similarity 43.9%; Pred. No. 7.7;
Matches 18; Conservative 13; Mismatches 10; Indels 0; Gaps 0;

QY 30 UCGACUCCGUCUCCUUAACACAGUUAUAAUUGGUUUUUA 70
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 182 TAGCTGGGCATCTTCATGCCAGTGATATTTGGTTTGA 222
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

RESULT 15
US-09-328-352-1916/c
; Sequence 1916, Application US/09328352
; Patent No. 6562958
; GENERAL INFORMATION:
; APPLICANT: Gary L. Breton et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO ACINETOBACTER
; TITLE OF INVENTION: BAUMANNII FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: GTC99-03PA
; CURRENT APPLICATION NUMBER: US/09/328,352
; CURRENT FILING DATE: 1999-06-04
; NUMBER OF SEQ ID NOS: 8252
; SEQ ID NO 1916
; LENGTH: 960
; TYPE: DNA
; ORGANISM: Acinetobacter baumannii
US-09-328-352-1916

Query Match 25.0%; Score 25; DB 4; Length 960;
Best Local Similarity 36.9%; Pred. No. 12;
Matches 24; Conservative 16; Mismatches 25; Indels 0; Gaps 0;
QY 12 AAUUCACGAGGCAUUGCGACUCCGUCUUCUCAAACCAAGUUAUAAUUGGUUUUAG 71
Db 534 ATTGCTCTAGCAATACGGCGACTATATCGTTCTTACCATATTGATATGATATTGCG 475
QY 72 CAUUAU 76
Db 474 CAAAT 470

Search completed: November 30, 2004, 11:53:59
Job time : 58.1111 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 30, 2004, 11:12:15 ; Search time 231.667 Seconds
(without alignments)
2339.337 Million cell updates/sec

Title: US-09-529-397C-25

Perfect score: 100

Sequence: 1 gggaguggaggaaucaucg.....uagcgagcagaagcuucg 100

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 3640242 seqs, 2709731945 residues

Total number of hits satisfying chosen parameters: 7280484

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications NA.*

1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq.*
2: /cgn2_6/ptodata/2/pubpna/PCT_NEW_PUB.seq.*
3: /cgn2_6/ptodata/2/pubpna/US06_NEW_PUB.seq.*
4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq.*
5: /cgn2_6/ptodata/2/pubpna/US07_NEW_PUB.seq.*
6: /cgn2_6/ptodata/2/pubpna/PCTUS_PUBCOMB.seq.*
7: /cgn2_6/ptodata/2/pubpna/US08_NEW_PUB.seq.*
8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq.*
9: /cgn2_6/ptodata/2/pubpna/US09A_PUBCOMB.seq.*
10: /cgn2_6/ptodata/2/pubpna/US09B_PUBCOMB.seq.*
11: /cgn2_6/ptodata/2/pubpna/US09C_PUBCOMB.seq.*
12: /cgn2_6/ptodata/2/pubpna/US09_NEW_PUB.seq.*
13: /cgn2_6/ptodata/2/pubpna/US10A_PUBCOMB.seq.*
14: /cgn2_6/ptodata/2/pubpna/US10B_PUBCOMB.seq.*
15: /cgn2_6/ptodata/2/pubpna/US10C_PUBCOMB.seq.*
16: /cgn2_6/ptodata/2/pubpna/US10D_PUBCOMB.seq.*
17: /cgn2_6/ptodata/2/pubpna/US10E_PUBCOMB.seq.*
18: /cgn2_6/ptodata/2/pubpna/US10_NEW_PUB.seq.*
19: /cgn2_6/ptodata/2/pubpna/US11_NEW_PUB.seq.*
20: /cgn2_6/ptodata/2/pubpna/US60_NEW_PUB.seq.*
21: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query		Length	DB	ID	Description
		Match	%				
1	29.8	29.8	4285	14	US-10-104-580-1	Sequence 1, Appl1	
C 2	28.8	28.8	675	16	US-10-282-122A-40631	Sequence 40631, A	
C 3	28.6	28.6	2000	9	US-09-938-842A-2908	Sequence 2908, Ap	
C 4	28.6	28.6	2000	11	US-09-938-842A-2908	Sequence 2908, Ap	
C 5	28.2	28.2	586	16	US-10-425-114-30801	Sequence 30801, A	
C 6	28.2	28.2	1612	17	US-10-767-701-13576	Sequence 13576, A	
C 7	28.2	28.2	1851	18	US-10-425-115-121623	Sequence 121623, A	
C 8	28.0	1691139	14	US-10-067-514-1	Sequence 1, Appl1		
C 9	28.0	1691139	16	US-10-419-723-1	Sequence 1, Appl1		
C 10	27.8	27.8	1093	15	US-10-369-493-25760	Sequence 25760, A	
C 11	27.8	27.8	99291	17	US-10-322-281-744	Sequence 744, App	
C 12	27.0	27.0	522	15	US-10-097-111-47	Sequence 47, Appl	

13	27.0	56506	15	US-10-097-111-10	Sequence 10, Appli
14	26.8	1116	15	US-10-271-181B-6	Sequence 6, Appli
15	26.6	1884	15	US-10-369-493-35948	Sequence 35948, A
C 16	26.6	48995	16	US-10-052-482-85	Sequence 85, Appli
C 17	26.4	621	13	US-10-027-632-199104	Sequence 199104,
C 18	26.4	621	13	US-10-027-632-199104	Sequence 199104,
C 19	26.2	489	10	US-09-814-353-15351	Sequence 15351, A
C 20	26.2	502	13	US-10-027-632-324279	Sequence 324279,
C 21	26.2	502	13	US-10-027-632-324280	Sequence 324280,
C 22	26.2	502	15	US-10-027-632-324279	Sequence 324279,
C 23	26.2	502	15	US-10-027-632-324280	Sequence 324280,
C 24	26.2	181684	13	US-10-087-192-790	Sequence 790, App
C 25	26.0	368	16	US-10-424-599-130987	Sequence 130987,
C 26	26.0	725	13	US-10-027-632-150280	Sequence 150280,
C 27	26.0	725	13	US-10-027-632-150280	Sequence 150280,
C 28	26.0	740	13	US-10-027-632-14431	Sequence 14431, A
C 29	26.0	740	13	US-10-027-632-14432	Sequence 14432, A
C 30	26.0	740	15	US-10-027-632-14431	Sequence 14431, A
C 31	26.0	740	15	US-10-027-632-14432	Sequence 14432, A
C 32	26.0	2515	13	US-10-027-632-101724	Sequence 101724,
C 33	26.0	2515	15	US-10-027-632-101724	Sequence 101724,
C 34	26.0	7285	14	US-10-198-846-13160	Sequence 13160, A
C 35	26.0	8998	15	US-10-311-455-1680	Sequence 1680, Ap
C 36	25.8	798	8	US-08-781-986A-162	Sequence 162, App
C 37	25.8	798	16	US-10-329-624-162	Sequence 162, App
C 38	25.8	1165	18	US-10-425-115-310	Sequence 310, App
C 39	25.8	1550	17	US-10-437-963-73812	Sequence 73812, A
C 40	25.8	2577	17	US-10-437-963-73810	Sequence 73810, A
C 41	25.8	2688	17	US-10-437-963-73813	Sequence 73813, A
C 42	25.8	25320	13	US-10-087-192-253	Sequence 253, App
C 43	25.8	43980	16	US-10-398-221-5	Sequence 5, Appli
C 44	25.8	94330	13	US-10-087-192-1222	Sequence 1222, Ap
C 45	25.8	226215	13	US-10-087-192-1948	Sequence 1948, Ap

ALIGNMENTS

RESULT 1

US-10-104-580-1
; Sequence 1, Application US/10104580
; Publication No. US20030033628A1

; GENERAL INFORMATION:

; APPLICANT: Strauss et al.

; TITLE OF INVENTION: Floral homeotic genes for manipulation of flowering in
; FILE REFERENCE: 62486
; CURRENT APPLICATION NUMBER: US/10/104,580

; CURRENT FILING DATE: 2002-03-21

; PRIOR FILING DATE: 1999-10-01

; PRIOR APPLICATION NUMBER: 09/410,464

; PRIOR FILING DATE: 1999-10-01

; PRIOR APPLICATION NUMBER: 09/287,700

; PRIOR FILING DATE: 1999-04-06

; PRIOR APPLICATION NUMBER: 60/080,851

; PRIOR FILING DATE: 1998-04-06

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 1

; LENGTH: 4285

; TYPE: DNA

; ORGANISM: Populus balsamifera subsp. trichocarpa

US-10-104-580-1

Query Match 29.8; Score 29.8; DB 14; Length 4285;

Best Local Similarity 33.38; Pred. No. 9.7; Mismatches 32; Indels 0; Gaps 0;

Matches 27; Conservative 22;

QY 8 GAGGAUUCUUGCAGGCAUUGCAGCUCGCUUCCUUAACAGGUUAAUUGUU 67

DB 1193 GATTTAATCCGTAACTTCTTCTGTTTTTATGCTTCAATCCATCTATTATGTTT 1252

QY 68 UUAGCAUUGCCUAGCGACA 88


```
RESULT 5
US-10-425-114-30801/c
; Sequence 30801, Application US/10425114
; Publication No. US2004003488A1
; GENERAL INFORMATION:
; APPLICANT: Liu, Jirongdong
; APPLICANT: Zhou, Yihua
; APPLICANT: Kovalic, David K.
; APPLICANT: Screen, Steven E
; APPLICANT: Tabaska, Jack E
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof For Plant Improvement
; FILE REFERENCE: 38-21(53313)B
; CURRENT APPLICATION NUMBER: US/10/425,114
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 73128
; SEQ ID NO 30801
; LENGTH: 586
; TYPE: DNA
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: UC-ZMFLB73080F09_FLI
US-10-425-114-30801
Query Match      28.2%; Score 28.2; DB 16; Length 586;
Best Local Similarity 37.1%; Pred. No. 17;
Matches 33; Conservative 18; Mismatches 38; Indels 0; Gaps 0;
QY 8 GAGGAUUAUCGAGCAUUGUGACUCCGUCUCCUACCAACAGUUAUAAUUGGUU 67
Db 92 GGGGCATTTTATGTTGTTATTAGGATTTCTCTGCTCCACCGGCATCACTCGGTT 33
QY 68 UUAGCAUAUCCUUAAGCAGCAGCAAGCUU 96
Db 32 CCAGCAAGCGCATTAGGGAAGGAAGATT 4
RESULT 6
US-10-767-701-13576/c
; Sequence 13576, Application US/10767701
; Publication No. US20040172684A1
; GENERAL INFORMATION:
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof For Plant Improvement
; FILE REFERENCE: 38-21(53535)B
; CURRENT APPLICATION NUMBER: US/10/767,701
; CURRENT FILING DATE: 2004-01-29
; NUMBER OF SEQ ID NOS: 63128
; SEQ ID NO 13576
; LENGTH: 1612
; TYPE: DNA
; ORGANISM: Sorghum bicolor
; FEATURE:
; OTHER INFORMATION: Clone ID: SORBI-28MAY03-CLUS1303_1
US-10-767-701-13576
Query Match      28.2%; Score 28.2; DB 17; Length 1612;
Best Local Similarity 38.2%; Pred. No. 24;
Matches 34; Conservative 17; Mismatches 38; Indels 0; Gaps 0;
QY 8 GAGGAUUAUCGAGCAUUGUGACUCCGUCUCCUACCAACAGUUAUAAUUGGUU 67
Db 1152 GGGGCATTTTATGTTGTTATTAGGATTTCTCTGCTCCACCGGCATCACTCGGTT 1093
QY 68 UUAGCAUAUCCUUAAGCAGCAGCAAGCUU 96
Db 1092 CCAGCAAGCGCATTAGGGAAGGAAGATT 1064
```

```
RESULT 7
US-10-425-115-121623/c
; Sequence 121623, Application US/10425115
; Publication No. US2004024272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 121623
; LENGTH: 1851
; TYPE: DNA
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_42398C.1
US-10-425-115-121623
Query Match      28.2%; Score 28.2; DB 18; Length 1851;
Best Local Similarity 37.1%; Pred. No. 26;
Matches 33; Conservative 18; Mismatches 38; Indels 0; Gaps 0;
QY 8 GAGGAUUAUCGAGCAUUGUGACUCCGUCUCCUACCAACAGUUAUAAUUGGUU 67
Db 1333 GGGGCATTTTATGTTGTTATTAGGATTTCTCTGCTCCACCGGCATCACTCGGTT 1274
QY 68 UUAGCAUAUCCUUAAGCAGCAGCAAGCUU 96
Db 1273 CCAGCAAGCGCATTAGGGAAGGAAGATT 1245
RESULT 8
US-10-067-514-1/c
; Sequence 1, Application US/10067514
; Publication No. US20030054531A1
; GENERAL INFORMATION:
; APPLICANT: Gretaarsdottir, Solveig
; APPLICANT: Jonsdottir, Sif
; APPLICANT: Reynisdottir, Sigridur Th.
; TITLE OF INVENTION: HUMAN STROKE GENE
; FILE REFERENCE: 2345.2010-003
; CURRENT APPLICATION NUMBER: US/10/067,514
; CURRENT FILING DATE: 2002-02-04
; PRIOR APPLICATION NUMBER: US 09/811/352
; PRIOR FILING DATE: 2001-03-19
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 1691139
; TYPE: DNA
; ORGANISM: Human
US-10-067-514-1
Query Match      28.0%; Score 28; DB 14; Length 1691139;
Best Local Similarity 41.7%; Pred. No. 3.6e+02;
Matches 25; Conservative 15; Mismatches 20; Indels 0; Gaps 0;
QY 12 AAUUAUCGAGCAUUGUGACUCCGUCUCCUACCAACAGUUAUAAUUGGUUAG 71
Db 127542 AGTTGATCCATGCTTTTGGAGGGAGCTTATCCCTTCAAAGCAGTAATAAAGTCTTTTAG 127483
RESULT 9
US-10-419-723-1/c
; Sequence 1, Application US/10419723
; Publication No. US20040014099A1
; GENERAL INFORMATION:
; APPLICANT: Gretaarsdottir, Solveig
```



```

Query Match      26.8%; Score 26.9; DB 15; Length 1116;
Best Local Similarity 38.4%; Pred. No. 65;
Matches 33; Conservative 16; Mismatches 37; Indels 0; Gaps 0;

QY      6  UGGAGGAAUUCAGUGAGGCGAAUUGCAGCUCGCUUCCUUCACACAGUUAUAUUGG 65
      : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : |||

```

```
Query Match          26.68; Score 26.6; DB 15; Length 1894;
Best Local Similarity 49.04; Pred.No. 94;
Matches 24; Conservative 11; Mismatches 14; Indels 0; Gaps 0
```



```
Qy      26 UAUGUCGACUCCGUUUUUCUUAACAACAGUUAUAAAUUGGUUUUAGAUAU 74
       :|||:|||::|||||::|::|::|::|::|::|::|::|::|::|::|::|::
Db     364 TATGGCGAGGCCGTGCGCCCATCAAACCGGTATGAATTGGCTCGCCT 412
```



```
Search completed: November 30, 2004, 12:01:02
Job time : 237.667 secs
```

